{"gene":"ITGA2B","run_date":"2026-06-10T01:55:23","timeline":{"discoveries":[{"year":1987,"finding":"GPIIb is synthesized in megakaryocytes as a precursor of Mr 130,000 containing both alpha and beta subunits; this precursor is processed with a half-life of 4–5 h, converting high-mannose oligosaccharides to complex-type carbohydrates to yield mature GPIIb alpha (116 kDa) and GPIIb beta (25 kDa) subunits. GPIIIa polypeptide backbone is 90 kDa with no detectable post-translational processing of the chain.","method":"Pulse-chase metabolic labeling with [35S]methionine, immunoprecipitation with subunit-specific antibodies, tunicamycin/monensin treatment, endoglycosidase H digestion of purified human megakaryocytes","journal":"The Journal of cell biology","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vitro biosynthesis assay with multiple orthogonal biochemical methods (pulse-chase, glycosidase treatment, inhibitor studies) in primary human megakaryocytes","pmids":["3108266"],"is_preprint":false},{"year":1989,"finding":"Assembly of pro-GPIIb with GPIIIa is an obligatory step for maturation of the GPIIb-IIIa heterodimer and its surface expression. A large pool (~60%) of unassociated GPIIIa exists and is not surface-exposed; GPIIb and pro-GPIIb molecules are nearly all found associated with GPIIIa. Expression of GPIIIa in a megakaryocytic cell line that only produces pro-GPIIb (and cannot process it) rescues mature GPIIb production and surface expression of the complex.","method":"Pulse-chase experiments, immunoprecipitation with subunit-specific antibodies on human megakaryocytes and the LAMA-84 megakaryocytic cell line, co-transfection rescue experiments","journal":"Blood","confidence":"High","confidence_rationale":"Tier 1 / Strong — reconstitution/rescue experiment plus pulse-chase, reciprocal IP, replicated in two cell systems","pmids":["2477081"],"is_preprint":false},{"year":1990,"finding":"Full-length cDNA sequences for GPIIb and GPIIIa were determined from human megakaryocyte cDNA libraries, revealing a nucleotide difference at position 633 of GPIIb (cysteine in megakaryocyte vs. serine in HEL cells) and differences in GPIIIa sequence compared to endothelial cell-derived cDNA.","method":"cDNA library construction from human megakaryocytes, cDNA sequencing","journal":"Molecular biology reports","confidence":"Medium","confidence_rationale":"Tier 1 / Weak — primary sequence determination from megakaryocyte cDNA, single lab, single method","pmids":["2345548"],"is_preprint":false},{"year":1991,"finding":"The 5'-flanking region of the GPIIb gene (from -643 to +33) drives megakaryocyte-specific transcription. Two domains at positions -460 and -510 interact exclusively with proteins present in megakaryocytic cells and act as positive transcription factor binding sites; deletion of this region significantly decreases promoter activity. Other domains (at -54, -233, -345, -540) bind more broadly expressed nuclear factors.","method":"CAT reporter transfection in megakaryocytic and non-megakaryocytic cells, DNase I footprinting, gel mobility shift assays","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Moderate — functional promoter deletion analysis combined with protein-DNA interaction assays (footprinting + EMSA), single lab with multiple orthogonal methods","pmids":["2026605"],"is_preprint":false},{"year":1992,"finding":"The transmembrane and cytoplasmic domains of the GPIIb (alphaIIb) subunit are necessary for surface expression of the GPIIb-IIIa complex, whereas the corresponding domains of GPIIIa (beta3) are not required. The extracellular domains of both subunits can form a heterodimer in the absence of transmembrane/cytoplasmic domains, albeit with lower efficiency.","method":"COS cell transfection with full-length and deletion mutant cDNAs (GPIIb delta1 lacking TM/cytoplasmic domain; GPIIIa delta-m lacking TM/cytoplasmic domain), immunoprecipitation, immunofluorescence","journal":"Biochemistry","confidence":"High","confidence_rationale":"Tier 1 / Moderate — domain deletion mutagenesis with functional surface expression readout and Co-IP, single lab with multiple orthogonal methods","pmids":["1540596"],"is_preprint":false},{"year":1991,"finding":"Binding of the anti-GPIIIa monoclonal antibody D3GP3 to GPIIIa within intact GPIIb-IIIa complexes induces fibrinogen binding and platelet aggregation without triggering Ca2+ mobilization, protein phosphorylation, or pertussis toxin-sensitive G-protein activation, and the aggregation is not blocked by PGE1, aspirin, or apyrase. This demonstrates that a conformational change in GPIIb-IIIa can expose the fibrinogen receptor in an activation-independent fashion.","method":"Platelet aggregometry, Ca2+ mobilization assay, protein phosphorylation analysis, pertussis toxin treatment, pharmacologic inhibitor panel, scanning electron microscopy","journal":"Thrombosis research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — antibody-induced conformational change with multiple functional readouts and pharmacologic controls, single lab","pmids":["1957276"],"is_preprint":false},{"year":1991,"finding":"Anti-CD41 IgG antibody (UR1) activates platelets via an Fc receptor-dependent cell-cell interaction mechanism: UR1 binds CD41 on one platelet forming immune complexes that then crosslink and stimulate FcgammaRII on adjacent platelets. F(ab')2 fragments of UR1 fail to activate platelets and inhibit IgG-mediated activation; anti-FcgammaRII antibody blocks activation; high-viscosity media that impede cell-cell contact inhibit activation.","method":"Platelet aggregometry, Ca2+ mobilization assay, F(ab')2 fragment generation, anti-FcgammaRII blocking antibody, high-viscosity inhibition, cell-mixing experiments","journal":"British journal of haematology","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal experiments (F(ab')2, receptor blocking, cell mixing, viscosity) converging on same mechanism","pmids":["1832937"],"is_preprint":false},{"year":1995,"finding":"GPIIb-IIIa (alphaIIbbeta3) is the platelet receptor for fibrinogen and mediates platelet aggregation induced by all physiologic agonists; blockade with the Fab fragment of chimeric monoclonal antibody 7E3 (abciximab), RGD-containing snake venom peptides, or RGD-based peptidomimetics abolishes platelet aggregation and platelet thrombus formation.","method":"In vitro platelet aggregation assay, in vivo animal thrombosis models, EPIC Phase III clinical trial","journal":"Thrombosis and haemostasis","confidence":"High","confidence_rationale":"Tier 2 / Strong — replicated across multiple labs, animal models, and a large clinical trial; multiple inhibitor classes converge on same receptor-ligand mechanism","pmids":["8578476"],"is_preprint":false},{"year":1996,"finding":"A homozygous nonsense mutation (Ser870→stop) in the GPIIb heavy chain truncates GPIIb by 138 amino acids, removing the transmembrane and intracytoplasmic domains. The truncated GPIIb can associate with GPIIIa, but the heterodimer fails to mature (as shown by endoglycosidase H sensitivity) and is not expressed on the cell surface, establishing that the GPIIb light chain region is required for maturation and surface trafficking.","method":"Cotransfection of mutant GPIIb and wild-type GPIIIa in COS-7 cells, immunoprecipitation, endoglycosidase H digestion, flow cytometry","journal":"British journal of haematology","confidence":"High","confidence_rationale":"Tier 1 / Moderate — disease mutation with reconstitution in COS cells, endoglycosidase H assay to assess maturation, and surface expression readout; single lab with multiple orthogonal methods","pmids":["8904900"],"is_preprint":false},{"year":2004,"finding":"ERK signaling promotes megakaryocyte differentiation by driving transcription from the proximal GPIIb (CD41) promoter (within 114 bp upstream of the TSS). GATA, Ets, and Sp1 consensus sequences within this region each function combinatorially and are each necessary for ERK-activated transcription. ERK induces MafB/Kreisler, which synergizes with GATA and Ets factors to enhance GPIIb promoter activity; dominant-negative or antisense suppression of MafB inhibits ERK-dependent transactivation.","method":"Promoter-reporter transfection assays, site-directed mutagenesis of GATA/Ets/Sp1 sites, dominant-negative and antisense MafB constructs, megakaryocyte differentiation assays","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 1 / Moderate — multiple orthogonal promoter deletion/mutagenesis experiments with loss-of-function of MafB, single lab","pmids":["15121870"],"is_preprint":false},{"year":2004,"finding":"Combined G(i) and G(z) signaling pathways activate platelet GPIIb/IIIa and cause platelet aggregation through a mechanism that requires Src family tyrosine kinases but shows only a minor calcium requirement, distinct from the G(q)+G(i) pathway which is dependent on intracellular calcium but insensitive to Src family kinase inhibitors. Src family kinase inhibitor PP2 inhibits PAC-1 binding (GPIIb/IIIa activation) and thromboxane generation downstream of G(i)+G(z) but not G(q)+G(i).","method":"Platelet aggregometry, PAC-1 binding by flow cytometry, intracellular calcium chelation (BAPTA-AM), PP2 Src kinase inhibition, aspirin treatment, G-protein pathway-selective agonists, P2Y1-deficient and Galpha(q)-deficient mouse platelets","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic knockout mice plus pharmacologic dissection using multiple selective inhibitors and multiple readouts, single lab with strong convergent evidence","pmids":["15546949"],"is_preprint":false},{"year":2003,"finding":"CBFA2 (RUNX1) mutation in a patient is associated with decreased platelet PKC-theta and impaired receptor-mediated GPIIb-IIIa activation and pleckstrin phosphorylation, demonstrating that PKC-theta and proteins regulated by CBFA2 are required for inside-out signal transduction leading to GPIIb-IIIa activation.","method":"Platelet RNA sequencing (exon amplification), immunoblotting for PKC isoforms and pleckstrin, flow cytometry for GPIIb-IIIa activation (PAC-1), functional aggregation assays","journal":"Blood","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — single patient with multiple biochemical readouts linking transcription factor mutation to integrin activation pathway; single lab, limited to one case","pmids":["14525764"],"is_preprint":false},{"year":2005,"finding":"ADAM15 (metargidin) functions as an adhesion receptor for platelet GPIIb-IIIa. Soluble ADAM15 binds to activated but not resting GPIIb-IIIa. Platelet adhesion to immobilized ADAM15 is blocked by anti-alphaIIbbeta3 mAbs (7E3, 2G12) but not by anti-alphavbeta3 (LM609). Adhesion to ADAM15 triggers platelet activation including CD62P secretion and CD40L release.","method":"Platelet adhesion assay under static and shear conditions, neutralizing anti-integrin mAbs, flow cytometry for activation markers (CD62P, CD40L), ADAM15 overexpression on endothelial cells","journal":"Thrombosis and haemostasis","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — binding specificity established with multiple blocking antibodies and multiple activation readouts; single lab","pmids":["16268472"],"is_preprint":false},{"year":2006,"finding":"S. aureus fibronectin-binding proteins FnBPA and FnBPB activate platelets via two distinct bridges to the low-affinity form of GPIIb/IIIa on resting platelets: (i) fibrinogen bridging to the A domain and (ii) fibronectin bridging to the BCD region. Antibodies recognizing FnBPA engage platelet FcgammaRIIa to complete activation; blocking GPIIb/IIIa or FcgammaRIIa (mAb IV-3) inhibits activation.","method":"Platelet aggregation assays, domain-truncation constructs of FnBPA expressed on S. aureus and L. lactis, blocking antibodies against GPIIb/IIIa and FcgammaRIIa","journal":"Molecular microbiology","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple truncation constructs dissecting two independent mechanisms, receptor-blocking experiments, heterologous expression system; replicated across multiple bacterial strains","pmids":["16359330"],"is_preprint":false},{"year":2007,"finding":"Platelet-derived microparticles (PMPs) transfer functional GPIIb/IIIa receptors to neutrophils. On GM-CSF-treated neutrophils, acquired GPIIb/IIIa co-localizes with beta2-integrins and cooperates with them to activate NF-kappaB via Src, Syk, and the actin cytoskeleton. Blocking either beta2-integrins or GPIIb/IIIa abrogates fibronectin-induced NF-kappaB activation and TNF-alpha mRNA upregulation in PMP-loaded neutrophils.","method":"Flow cytometry and confocal microscopy for receptor surface expression, NF-kappaB Western blot and EMSA, RT-PCR for TNF-alpha, kinase inhibitors (Src, Syk), blocking antibodies, therapeutic GPIIb/IIIa inhibitors","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — confocal co-localization plus functional NF-kappaB assays with multiple inhibitors; single lab","pmids":["17644514"],"is_preprint":false},{"year":2011,"finding":"A heterozygous ITGA2B R995W (αIIb-W995) mutation induces constitutive activation of the αIIbβ3 receptor as shown by spontaneous PAC-1 and fibrinogen binding to resting platelets, and spontaneous FAK phosphorylation in transfected 293T cells. The activated αIIb-W995/β3 causes membrane ruffling and abnormal cytoplasmic protrusions in transfected CHO cells, and increases proplatelet tip size/decreases tip number in mouse fetal liver-derived megakaryocytes, establishing a mechanism for congenital macrothrombocytopenia.","method":"Flow cytometry (PAC-1, fibrinogen binding), FAK phosphorylation by Western blot, 293T and CHO cell transfection with mutant constructs, mouse fetal liver megakaryocyte transduction, proplatelet formation assay","journal":"Blood","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — multiple orthogonal functional assays (binding, phosphorylation, morphology, proplatelet formation), cell-based reconstitution in multiple systems, confirmed in 4 unrelated families","pmids":["21454453"],"is_preprint":false},{"year":2012,"finding":"Itga2b expression in hematopoietic cells is regulated by lineage-specific epigenetic mechanisms: H4K8 acetylation marks the locus in megakaryocytes, while H3K27me3 represses it in multipotential hematopoietic progenitors (HPC7 cells). Commitment to megakaryocyte differentiation is accompanied by upregulation of the H3K27 demethylase Jmjd3, which correlates with decreased H3K27me3 at the Itga2b locus and increased CD41 expression. An internal promoter mechanism also participates in developmental regulation.","method":"Chromatin immunoprecipitation (H4K8ac, H3K27me3), RT-PCR for Jmjd3 and Itga2b, promoter analysis in multiple hematopoietic cell contexts","journal":"PloS one","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP for histone marks and correlation with Jmjd3 induction, multiple cell types; single lab, correlative element without Jmjd3 direct KO at this locus","pmids":["22952660"],"is_preprint":false},{"year":2023,"finding":"Integrin GPIIb (αIIb)-dependent outside-in signaling via Gα13 coordinates platelet polarization during migration by triggering a c-Src/14-3-3ζ-dependent lamellipodium formation pathway. This pathway is independent of soluble agonists or chemotactic signals and requires anisotropic myosin IIa activity at the platelet rear preceded by polarized actin polymerization at the front. Dasatinib (ABL/c-Src inhibitor) and other inhibitors of this cascade selectively impair platelet migration without major effects on classical platelet functions.","method":"Time-resolved morphodynamic profiling of individual platelets, pharmacologic inhibitors (dasatinib and others), murine inflammation models with 4D intravital microscopy, patient platelets from dasatinib-treated leukemia patients, actin/myosin perturbation experiments","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal methods (live imaging, pharmacology, in vivo mouse models, patient samples), pathway dissection with selective inhibitors, replicated across systems","pmids":["37018659"],"is_preprint":false},{"year":2020,"finding":"CD41 (integrin α2b) in exosomes activates a CD41-integrin β3-FAK-Akt-Runx2 signaling pathway to support osteogenic differentiation and migration of mesenchymal stem cells. Exosomes from osteonecrosis of the femoral head (ONFH) tissue are deficient in CD41, and downregulation of CD41 in normal exosomes impairs this pathway and reduces MSC osteogenic differentiation and migration.","method":"Proteomic analysis of ONFH exosomes vs. normal exosomes, siRNA knockdown of CD41 in MSCs, Western blot for FAK/Akt/Runx2 phosphorylation, osteogenic differentiation assays, migration assays, rat in vivo ONFH model","journal":"Cell death & disease","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — loss-of-function (siRNA) with defined pathway readout (FAK-Akt-Runx2 phosphorylation) and functional cellular phenotype; single lab","pmids":["32341357"],"is_preprint":false},{"year":1988,"finding":"A GPIIb-IIIa-related protein in endothelial cells localizes to vinculin-rich focal contacts at stress fiber membrane insertions and to cell-to-cell contacts. Anti-GPIIb-IIIa antibodies added to endothelial cell suspensions inhibit spreading on fibrinogen and vitronectin substrata but are poorly active on fibronectin; antibodies added to adherent cells disrupt cell-to-cell contacts and cause rounding and detachment.","method":"Immunofluorescence localization, polyclonal anti-GPIIb-IIIa antibody inhibition of endothelial cell spreading on different matrix substrates, antibody-induced detachment assay","journal":"Blood","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct localization by immunofluorescence with functional consequence (inhibition of spreading and adhesion); note this uses a cross-reactive endothelial form; single lab","pmids":["3345337"],"is_preprint":false},{"year":1990,"finding":"When platelets are treated with monoclonal antibodies Tab (anti-GPIIb) and AP3 (anti-GPIIIa) together and stimulated with ADP, they form short blunted projections instead of normal filopodia, sequester GPIIb-IIIa and fibrinogen into the surface-connected canalicular system via massive actomyosin-controlled membrane flow, and fail to aggregate despite normal fibrinogen binding. This indicates that GPIIb-IIIa plays a role in signaling cytoskeletal rearrangements required for filopodium formation and aggregation.","method":"Scanning and transmission electron microscopy, immunolabel-surface replication, immunocytochemistry on frozen sections, biochemical cytoskeletal activation assays, platelet aggregometry","journal":"Blood","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple ultrastructural and biochemical methods characterizing a distinct post-fibrinogen-binding defect; single lab","pmids":["2207330"],"is_preprint":false},{"year":1995,"finding":"During platelet spreading, GPIIb-IIIa complexes pre-labeled with fibrinogen-coated gold particles translocate from uniform surface distribution to caps over cell centers and into channels of the open canalicular system (OCS), while GPIb/IX pre-labeled with vWF moves with the expanding cell membrane toward peripheral margins. These two receptor populations thus undergo distinct directional redistribution during spreading.","method":"Pre-labeling of discoid platelets with fibrinogen-coated gold or vWF/protein A-gold, electron microscopy, immunolabel-surface replication, cytochalasin E treatment to preserve discoid shape","journal":"British journal of haematology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct ultrastructural localization with specific gold-labeled ligands tracking receptor movement during defined functional event; single lab","pmids":["7647005"],"is_preprint":false},{"year":2022,"finding":"Cooperative signaling of platelet CLEC-2 and GPIIb/IIIa triggers cerebral venous sinus thrombosis (CVT)-like syndrome in mice within minutes. Pharmacological inhibition of GPIIb/IIIa (or CLEC-2 signaling) completely blocks platelet activation and CVT, and GPIIb/IIIa blockade after onset of neurological symptoms rescues mice from platelet consumption and death, demonstrating a mechanistic role for GPIIb/IIIa in pathological platelet activation underlying CVT.","method":"Antibody-induced mouse CVT model (INU1-fab), intravital transcranial microscopy, pharmacologic GPIIb/IIIa inhibition, CLEC-2 signaling blockade, heparin comparison, brain autopsy","journal":"Nature cardiovascular research","confidence":"High","confidence_rationale":"Tier 2 / Strong — in vivo mouse model with real-time intravital imaging, genetic/pharmacologic dissection of two receptor pathways, therapeutic rescue experiment","pmids":["39195988"],"is_preprint":false},{"year":2005,"finding":"GPIIb (CD41) integrin is expressed on cultured bone marrow mast cells (human and murine). Loss of GPIIb in gpIIb-/- mice does not affect mast cell growth or differentiation markers but results in altered adhesion to fibronectin- and vitronectin-coated surfaces and increased surface expression of αV integrin as a compensatory response.","method":"Flow cytometry of bone marrow mast cells from wild-type and gpIIb-/- mice, adhesion assays on matrix-coated surfaces, analysis of peritoneal mast cells in vivo","journal":"Experimental hematology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — knockout mouse comparison with functional adhesion assay and in vivo tissue mast cell analysis; single lab","pmids":["15781330"],"is_preprint":false}],"current_model":"ITGA2B (αIIb) assembles co-translationally with GPIIIa (β3) as an obligate prerequisite for heterodimer maturation and surface expression; the transmembrane/cytoplasmic domain of αIIb is required for surface trafficking while that of β3 is dispensable; on the platelet surface the αIIbβ3 complex is maintained in a low-affinity state and is activated by inside-out signaling through convergent G-protein pathways (Gq+Gi or Gi+Gz, the latter requiring Src family kinases) to bind fibrinogen, von Willebrand factor, and other RGD-containing ligands and mediate platelet aggregation; outside-in signaling through αIIb via Gα13 and a c-Src/14-3-3ζ axis drives lamellipodia formation and platelet migration; gain-of-function mutations (e.g. R995W) constitutively activate the receptor, causing macrothrombocytopenia through defective proplatelet formation; tissue-specific transcription is controlled by megakaryocyte-specific promoter elements binding GATA, Ets, Sp1, and ERK-induced MafB/Kreisler factors, and the locus is epigenetically regulated by H3K27me3/Jmjd3 during hematopoietic commitment."},"narrative":{"mechanistic_narrative":"ITGA2B (αIIb/GPIIb) is the platelet-specific α subunit that pairs obligately with β3 (GPIIIa) to form the αIIbβ3 (GPIIb-IIIa) integrin, the principal receptor mediating fibrinogen binding and platelet aggregation induced by physiologic agonists [PMID:8578476]. The subunit is synthesized in megakaryocytes as a glycosylated precursor whose assembly with β3 is an obligatory checkpoint for heterodimer maturation and surface expression; unassembled β3 is retained intracellularly, and co-expression of β3 rescues maturation of αIIb [PMID:3108266, PMID:2477081]. The transmembrane and cytoplasmic domains of αIIb — but not those of β3 — are required for surface trafficking of the complex, a requirement underscored by a disease truncation (Ser870→stop) that permits heterodimer association yet abolishes maturation and surface display [PMID:1540596, PMID:8904900]. On the platelet surface the receptor is held in a low-affinity state and switches to a fibrinogen-competent conformation through inside-out signaling; convergent G-protein routes (Gq+Gi versus Gi+Gz) drive this activation, with the Gi+Gz pathway requiring Src-family kinases and the Gq+Gi pathway being calcium-dependent [PMID:15546949], and upstream transcription-factor programs (RUNX1/CBFA2-PKCθ) feed into this inside-out cascade [PMID:14525764]. Beyond ligand capture, αIIb-dependent outside-in signaling through Gα13 and a c-Src/14-3-3ζ axis organizes lamellipodium formation and directional platelet migration [PMID:37018659], and the engaged receptor couples to actomyosin-driven cytoskeletal rearrangement required for filopodium formation and aggregation [PMID:2207330]. A gain-of-function mutation (R995W) constitutively activates the receptor, producing spontaneous ligand binding and FAK phosphorylation and causing macrothrombocytopenia through defective proplatelet formation [PMID:21454453]. Transcription of the gene is restricted to the megakaryocytic lineage by promoter elements bound combinatorially by GATA, Ets, and Sp1 factors and by ERK-induced MafB, and the locus is epigenetically gated by H3K27me3/Jmjd3 during hematopoietic commitment [PMID:2026605, PMID:15121870, PMID:22952660]. The receptor also participates in pathological thrombosis (e.g., CLEC-2–cooperative cerebral venous sinus thrombosis) and serves as a validated antithrombotic drug target [PMID:8578476, PMID:39195988].","teleology":[{"year":1987,"claim":"Established how αIIb is produced and processed in its native cell, defining the biosynthetic substrate from which the mature receptor is built.","evidence":"Pulse-chase metabolic labeling with glycosidase/inhibitor treatment in primary human megakaryocytes","pmids":["3108266"],"confidence":"High","gaps":["Did not address how assembly with β3 controls processing","No structural detail of the precursor"]},{"year":1989,"claim":"Showed that αIIb-β3 assembly is the obligatory gate for heterodimer maturation and surface expression, explaining why neither subunit reaches the surface alone.","evidence":"Pulse-chase, reciprocal immunoprecipitation, and β3 co-expression rescue in megakaryocytes and the LAMA-84 cell line","pmids":["2477081"],"confidence":"High","gaps":["Did not map which domains mediate the assembly requirement","ER retention machinery for unassembled subunits not identified"]},{"year":1990,"claim":"Determined the full-length αIIb (and β3) coding sequence, providing the molecular framework for mutagenesis and disease-variant analysis.","evidence":"cDNA library construction and sequencing from human megakaryocytes","pmids":["2345548"],"confidence":"Medium","gaps":["Single-lab sequence; cell-type sequence differences not functionally validated","No structure-function annotation"]},{"year":1991,"claim":"Localized the megakaryocyte-specific transcriptional control to defined 5'-flanking elements, beginning the explanation of why the gene is lineage-restricted.","evidence":"CAT reporter deletions, DNase I footprinting, and EMSA in megakaryocytic vs non-megakaryocytic cells","pmids":["2026605"],"confidence":"High","gaps":["Identity of the megakaryocyte-specific binding factors not determined here","Did not link promoter activity to differentiation signals"]},{"year":1991,"claim":"Demonstrated that a conformational change in the heterodimer alone can expose the fibrinogen receptor, dissociating receptor activation from canonical intracellular signaling.","evidence":"Antibody (D3GP3)-induced aggregation with Ca2+, phosphorylation, G-protein, and pharmacologic controls","pmids":["1957276"],"confidence":"Medium","gaps":["Structural basis of the conformational switch not resolved","Single-lab antibody-based perturbation"]},{"year":1991,"claim":"Clarified that some anti-CD41 antibodies activate platelets indirectly via FcgammaRII crosslinking rather than through direct receptor signaling, distinguishing artefactual from intrinsic activation.","evidence":"F(ab')2 fragments, anti-FcgammaRII blockade, cell-mixing and viscosity experiments","pmids":["1832937"],"confidence":"High","gaps":["Does not address physiologic inside-out activation","Mechanism specific to IgG immune complexes"]},{"year":1992,"claim":"Mapped the trafficking determinant to the αIIb transmembrane/cytoplasmic region, showing β3's cytoplasmic tail is dispensable for surface expression.","evidence":"COS-cell transfection with TM/cytoplasmic deletion mutants, Co-IP, and immunofluorescence","pmids":["1540596"],"confidence":"High","gaps":["Did not identify the trafficking machinery engaging the αIIb tail","Lower-efficiency extracellular dimerization not mechanistically explained"]},{"year":1995,"claim":"Cemented αIIbβ3 as the universal fibrinogen receptor for platelet aggregation and validated it as an antithrombotic target across inhibitor classes.","evidence":"In vitro aggregation, animal thrombosis models, and a Phase III clinical trial with abciximab and RGD-based inhibitors","pmids":["8578476"],"confidence":"High","gaps":["Did not dissect upstream activation pathways","Outside-in signaling roles not addressed"]},{"year":1990,"claim":"Linked receptor engagement to actomyosin-driven cytoskeletal remodeling, revealing a signaling role beyond passive ligand binding.","evidence":"EM, immunolabel-surface replication, and cytoskeletal/aggregation assays with anti-GPIIb/anti-GPIIIa antibodies","pmids":["2207330"],"confidence":"Medium","gaps":["Molecular link between receptor and cytoskeleton not defined","Antibody-clamping artifact not fully excluded"]},{"year":1995,"claim":"Showed receptor-specific spatial sorting during spreading, with αIIbβ3 internalizing into the open canalicular system distinct from GPIb/IX redistribution.","evidence":"Gold-labeled ligand tracking by electron microscopy during platelet spreading","pmids":["7647005"],"confidence":"Medium","gaps":["Functional consequence of OCS sequestration unresolved","Trafficking mechanism not identified"]},{"year":2003,"claim":"Connected the RUNX1/CBFA2 transcriptional program to inside-out activation competence via PKC-theta and pleckstrin phosphorylation.","evidence":"Patient platelet analysis with immunoblotting, PAC-1 flow cytometry, and aggregation assays","pmids":["14525764"],"confidence":"Medium","gaps":["Single-patient observation","Direct RUNX1 targets controlling activation not fully enumerated"]},{"year":2004,"claim":"Resolved two divergent G-protein routes to inside-out activation, distinguishing a calcium-dependent Gq+Gi pathway from a Src-kinase-dependent Gi+Gz pathway.","evidence":"Aggregometry, PAC-1 binding, calcium chelation, PP2 inhibition, and knockout-mouse platelets","pmids":["15546949"],"confidence":"High","gaps":["Convergence point on the integrin tail not identified","Relative physiologic weighting of pathways unresolved"]},{"year":2004,"claim":"Defined the proximal promoter logic, showing GATA/Ets/Sp1 and ERK-induced MafB act combinatorially to drive megakaryocytic CD41 transcription.","evidence":"Promoter-reporter mutagenesis and dominant-negative/antisense MafB in differentiation assays","pmids":["15121870"],"confidence":"High","gaps":["Endogenous chromatin context not addressed here","Upstream ERK activators not specified"]},{"year":2005,"claim":"Extended the receptor's repertoire to non-canonical ligands and cell contexts, identifying ADAM15 as an activation-dependent adhesion ligand and documenting CD41 roles in mast cells.","evidence":"Adhesion assays with blocking antibodies and activation-marker flow cytometry; gpIIb-/- mast cell adhesion studies","pmids":["16268472","15781330"],"confidence":"Medium","gaps":["Physiologic relevance of ADAM15 engagement in vivo unclear","Mast cell adhesion phenotype is compensatory and indirect"]},{"year":2006,"claim":"Showed bacterial pathogens exploit the low-affinity receptor through fibrinogen/fibronectin bridges plus FcgammaRIIa, mechanistically linking αIIbβ3 to infective platelet activation.","evidence":"Aggregation assays with FnBPA truncation constructs in heterologous bacteria and receptor-blocking antibodies","pmids":["16359330"],"confidence":"High","gaps":["In vivo contribution to endocarditis not tested here","Does not address direct receptor conformation change"]},{"year":2007,"claim":"Demonstrated horizontal transfer of functional αIIbβ3 to neutrophils, where it cooperates with β2-integrins to drive NF-kappaB signaling, broadening the receptor's inflammatory role.","evidence":"Confocal co-localization, NF-kappaB Western/EMSA, RT-PCR, and Src/Syk inhibitors in PMP-loaded neutrophils","pmids":["17644514"],"confidence":"Medium","gaps":["Single-lab observation","In vivo significance of transferred receptor unestablished"]},{"year":2011,"claim":"Identified R995W as a constitutively activating mutation causing macrothrombocytopenia via defective proplatelet formation, mechanistically tying receptor activation state to thrombopoiesis.","evidence":"PAC-1/fibrinogen binding, FAK phosphorylation, cell-morphology assays, and proplatelet assays in transfected cells and fetal-liver megakaryocytes, confirmed in 4 families","pmids":["21454453"],"confidence":"High","gaps":["Precise structural mechanism of constitutive activation not detailed","Link between activation and proplatelet defect mechanistically incomplete"]},{"year":2012,"claim":"Added an epigenetic layer to lineage restriction, showing H3K27me3/Jmjd3 dynamics gate Itga2b expression during megakaryocytic commitment.","evidence":"ChIP for histone marks and RT-PCR for Jmjd3/Itga2b across hematopoietic cell types","pmids":["22952660"],"confidence":"Medium","gaps":["Correlative without direct Jmjd3 knockout at the locus","Internal promoter mechanism not fully resolved"]},{"year":2020,"claim":"Implicated CD41 in exosome-borne CD41–β3–FAK–Akt–Runx2 signaling supporting MSC osteogenesis, indicating a role outside hemostasis.","evidence":"Exosome proteomics, CD41 siRNA, FAK/Akt/Runx2 immunoblotting, and differentiation/migration assays with a rat ONFH model","pmids":["32341357"],"confidence":"Medium","gaps":["Single-lab study","How exosomal CD41 engages target-cell β3 not defined"]},{"year":2022,"claim":"Established αIIbβ3 as a driver and therapeutic target in pathological thrombosis, with receptor blockade rescuing CLEC-2-cooperative cerebral venous sinus thrombosis.","evidence":"Antibody-induced mouse CVT model with intravital imaging, pharmacologic GPIIb/IIIa and CLEC-2 blockade, and therapeutic rescue","pmids":["39195988"],"confidence":"High","gaps":["Molecular cooperation between CLEC-2 and αIIbβ3 signaling not fully mapped","Translation to human CVT therapy untested here"]},{"year":2023,"claim":"Defined an outside-in migration program in which αIIbβ3 couples to Gα13 and a c-Src/14-3-3ζ axis to polarize platelets, distinguishing migration from classical aggregation.","evidence":"Morphodynamic profiling, selective inhibitors (dasatinib), 4D intravital microscopy, patient platelets, and actin/myosin perturbation","pmids":["37018659"],"confidence":"High","gaps":["Structural basis of Gα13 coupling to αIIb tail unresolved","Physiologic triggers of the polarization program not fully defined"]},{"year":null,"claim":"How inside-out and outside-in signals are integrated at the αIIb cytoplasmic tail at the structural level, and how the same receptor switches between aggregation, migration, and pathological consumption programs, remains unresolved.","evidence":"","pmids":[],"confidence":"High","gaps":["No structural model of the activated cytoplasmic tail signaling complex in the corpus","Mechanistic determinants choosing migration vs aggregation outputs unknown","Integration of transcriptional/epigenetic control with receptor signaling not unified"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0098631","term_label":"cell adhesion mediator activity","supporting_discovery_ids":[7,12,19]},{"term_id":"GO:0060089","term_label":"molecular transducer activity","supporting_discovery_ids":[10,17,20]},{"term_id":"GO:0038024","term_label":"cargo receptor activity","supporting_discovery_ids":[7]}],"localization":[{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[1,4,21]},{"term_id":"GO:0005856","term_label":"cytoskeleton","supporting_discovery_ids":[20,17]}],"pathway":[{"term_id":"R-HSA-109582","term_label":"Hemostasis","supporting_discovery_ids":[7,10,22]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[10,17,15]},{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[3,9,16]}],"complexes":["αIIbβ3 (GPIIb-IIIa) integrin"],"partners":["ITGB3","FGA","ADAM15","SRC","YWHAZ"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"P08514","full_name":"Integrin alpha-IIb","aliases":["GPalpha IIb","GPIIb","Platelet membrane glycoprotein IIb"],"length_aa":1039,"mass_kda":113.4,"function":"Integrin alpha-IIb/beta-3 (ITGA2B:ITGB3) is a receptor for fibronectin, fibrinogen, plasminogen, prothrombin, thrombospondin and vitronectin. It recognizes the sequence R-G-D in a wide array of ligands. It recognizes the sequence H-H-L-G-G-G-A-K-Q-A-G-D-V in fibrinogen gamma chain (By similarity). Following activation integrin alpha-IIb/beta-3 brings about platelet/platelet interaction through binding of soluble fibrinogen (PubMed:9111081). This step leads to rapid platelet aggregation which physically plugs ruptured endothelial cell surface (By similarity). Integrin ITGA2B:ITGB3 is also the receptor of erythrocyte-specific ICAM4 ligand involved in heterotypic cell-cell adhesion between erythrocytes and activated platelets (PubMed:12477717)","subcellular_location":"Cell membrane","url":"https://www.uniprot.org/uniprotkb/P08514/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/ITGA2B","classification":"Not Classified","n_dependent_lines":37,"n_total_lines":1208,"dependency_fraction":0.030629139072847682},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/ITGA2B","total_profiled":1310},"omim":[{"mim_id":"621266","title":"FETOMATERNAL ALLOIMMUNE THROMBOCYTOPENIA 2; FMAIT2","url":"https://www.omim.org/entry/621266"},{"mim_id":"621264","title":"FETOMATERNAL ALLOIMMUNE THROMBOCYTOPENIA 1; FMAIT1","url":"https://www.omim.org/entry/621264"},{"mim_id":"620776","title":"THROMBOCYTOPENIA 13, SYNDROMIC; THC13","url":"https://www.omim.org/entry/620776"},{"mim_id":"619271","title":"BLEEDING DISORDER, PLATELET-TYPE, 24; BDPLT24","url":"https://www.omim.org/entry/619271"},{"mim_id":"619267","title":"GLANZMANN THROMBASTHENIA 2; GT2","url":"https://www.omim.org/entry/619267"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Approved","locations":[{"location":"Plasma membrane","reliability":"Approved"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"bone marrow","ntpm":15.7},{"tissue":"epididymis","ntpm":10.1},{"tissue":"lymphoid tissue","ntpm":11.7}],"url":"https://www.proteinatlas.org/search/ITGA2B"},"hgnc":{"alias_symbol":["CD41B","CD41","PPP1R93","GPIIb"],"prev_symbol":["GP2B"]},"alphafold":{"accession":"P08514","domains":[{"cath_id":"2.130.10.130","chopping":"35-482","consensus_level":"medium","plddt":96.5543,"start":35,"end":482},{"cath_id":"2.60.40.1460","chopping":"485-607_615-630","consensus_level":"high","plddt":92.1532,"start":485,"end":630},{"cath_id":"2.60.40.1510","chopping":"644-775","consensus_level":"high","plddt":90.5267,"start":644,"end":775},{"cath_id":"2.60.40.1530","chopping":"780-793_808-868_907-990","consensus_level":"high","plddt":90.0996,"start":780,"end":990}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P08514","model_url":"https://alphafold.ebi.ac.uk/files/AF-P08514-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P08514-F1-predicted_aligned_error_v6.png","plddt_mean":88.12},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=ITGA2B","jax_strain_url":"https://www.jax.org/strain/search?query=ITGA2B"},"sequence":{"accession":"P08514","fasta_url":"https://rest.uniprot.org/uniprotkb/P08514.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P08514/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P08514"}},"corpus_meta":[{"pmid":"9923894","id":"PMC_9923894","title":"Platelet GPIIb-IIIa blockers.","date":"1999","source":"Lancet (London, England)","url":"https://pubmed.ncbi.nlm.nih.gov/9923894","citation_count":409,"is_preprint":false},{"pmid":"16099879","id":"PMC_16099879","title":"Analysis of thrombocyte development in CD41-GFP transgenic zebrafish.","date":"2005","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/16099879","citation_count":320,"is_preprint":false},{"pmid":"12393529","id":"PMC_12393529","title":"Expression of CD41 marks the initiation of definitive hematopoiesis in the mouse embryo.","date":"2002","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/12393529","citation_count":298,"is_preprint":false},{"pmid":"18840725","id":"PMC_18840725","title":"The GPIIb/IIIa (integrin alphaIIbbeta3) odyssey: a technology-driven saga of a receptor with twists, turns, and even a bend.","date":"2008","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/18840725","citation_count":279,"is_preprint":false},{"pmid":"23564910","id":"PMC_23564910","title":"CD41 expression marks myeloid-biased adult hematopoietic stem cells and increases with age.","date":"2013","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/23564910","citation_count":276,"is_preprint":false},{"pmid":"12900455","id":"PMC_12900455","title":"CD41 expression defines the onset of primitive and definitive hematopoiesis in the murine embryo.","date":"2003","source":"Development (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/12900455","citation_count":263,"is_preprint":false},{"pmid":"12019160","id":"PMC_12019160","title":"Multiple roles for platelet GPIIb/IIIa and alphavbeta3 integrins in tumor growth, angiogenesis, and metastasis.","date":"2002","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/12019160","citation_count":195,"is_preprint":false},{"pmid":"18417622","id":"PMC_18417622","title":"CD41+ cmyb+ precursors colonize the zebrafish pronephros by a novel migration route to initiate adult hematopoiesis.","date":"2008","source":"Development (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/18417622","citation_count":182,"is_preprint":false},{"pmid":"21917754","id":"PMC_21917754","title":"Glanzmann thrombasthenia: a review of ITGA2B and ITGB3 defects with emphasis on variants, phenotypic variability, and mouse models.","date":"2011","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/21917754","citation_count":176,"is_preprint":false},{"pmid":"16359330","id":"PMC_16359330","title":"Fibronectin-binding proteins of Staphylococcus aureus mediate activation of human platelets via fibrinogen and fibronectin bridges to integrin GPIIb/IIIa and IgG binding to the FcgammaRIIa receptor.","date":"2006","source":"Molecular microbiology","url":"https://pubmed.ncbi.nlm.nih.gov/16359330","citation_count":165,"is_preprint":false},{"pmid":"11487034","id":"PMC_11487034","title":"Anti-GPIIb/IIIa drugs: current strategies and future directions.","date":"2001","source":"Thrombosis and haemostasis","url":"https://pubmed.ncbi.nlm.nih.gov/11487034","citation_count":143,"is_preprint":false},{"pmid":"11934866","id":"PMC_11934866","title":"Expression of CD41 on hematopoietic progenitors derived from embryonic hematopoietic cells.","date":"2002","source":"Development (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/11934866","citation_count":133,"is_preprint":false},{"pmid":"12958625","id":"PMC_12958625","title":"Inhibition of tumor cell-induced platelet aggregation and lung metastasis by the oral GpIIb/IIIa antagonist XV454.","date":"2003","source":"Thrombosis and haemostasis","url":"https://pubmed.ncbi.nlm.nih.gov/12958625","citation_count":121,"is_preprint":false},{"pmid":"8578476","id":"PMC_8578476","title":"New antiplatelet agents: platelet GPIIb/IIIa antagonists.","date":"1995","source":"Thrombosis and haemostasis","url":"https://pubmed.ncbi.nlm.nih.gov/8578476","citation_count":117,"is_preprint":false},{"pmid":"9198247","id":"PMC_9198247","title":"GPIIb/IIIa antagonists: pathophysiologic and therapeutic insights from studies of c7E3 Fab.","date":"1997","source":"Thrombosis and haemostasis","url":"https://pubmed.ncbi.nlm.nih.gov/9198247","citation_count":112,"is_preprint":false},{"pmid":"3108266","id":"PMC_3108266","title":"Biosynthesis and processing of platelet GPIIb-IIIa in human megakaryocytes.","date":"1987","source":"The Journal of cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/3108266","citation_count":96,"is_preprint":false},{"pmid":"2477081","id":"PMC_2477081","title":"Biosynthesis and assembly of platelet GPIIb-IIIa in human megakaryocytes: evidence that assembly between pro-GPIIb and GPIIIa is a prerequisite for expression of the complex on the cell surface.","date":"1989","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/2477081","citation_count":94,"is_preprint":false},{"pmid":"2026605","id":"PMC_2026605","title":"Tissue-specific expression of the platelet GPIIb gene.","date":"1991","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/2026605","citation_count":92,"is_preprint":false},{"pmid":"22370973","id":"PMC_22370973","title":"GPIIb/IIIa inhibitors: from bench to bedside and back to bench again.","date":"2012","source":"Thrombosis and haemostasis","url":"https://pubmed.ncbi.nlm.nih.gov/22370973","citation_count":85,"is_preprint":false},{"pmid":"21454453","id":"PMC_21454453","title":"Heterozygous ITGA2B R995W mutation inducing constitutive activation of the αIIbβ3 receptor affects proplatelet formation and causes congenital macrothrombocytopenia.","date":"2011","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/21454453","citation_count":77,"is_preprint":false},{"pmid":"8533122","id":"PMC_8533122","title":"Characterization of tumor-induced platelet aggregation: the role of immunorelated GPIb and GPIIb/IIIa expression by MCF-7 breast cancer cells.","date":"1995","source":"Thrombosis research","url":"https://pubmed.ncbi.nlm.nih.gov/8533122","citation_count":77,"is_preprint":false},{"pmid":"10226086","id":"PMC_10226086","title":"Quantifying GPIIb/IIIa receptor binding using 2 monoclonal antibodies: discriminating abciximab and small molecular weight antagonists.","date":"1999","source":"Circulation","url":"https://pubmed.ncbi.nlm.nih.gov/10226086","citation_count":76,"is_preprint":false},{"pmid":"25728920","id":"PMC_25728920","title":"Expanding the Mutation Spectrum Affecting αIIbβ3 Integrin in Glanzmann Thrombasthenia: Screening of the ITGA2B and ITGB3 Genes in a Large International Cohort.","date":"2015","source":"Human mutation","url":"https://pubmed.ncbi.nlm.nih.gov/25728920","citation_count":70,"is_preprint":false},{"pmid":"15725743","id":"PMC_15725743","title":"Endothelial cells in the early murine yolk sac give rise to CD41-expressing hematopoietic cells.","date":"2005","source":"Stem cells and development","url":"https://pubmed.ncbi.nlm.nih.gov/15725743","citation_count":70,"is_preprint":false},{"pmid":"11264167","id":"PMC_11264167","title":"Different expression of CD41 on human lymphoid and myeloid progenitors from adults and neonates.","date":"2001","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/11264167","citation_count":67,"is_preprint":false},{"pmid":"14525764","id":"PMC_14525764","title":"Association of CBFA2 mutation with decreased platelet PKC-theta and impaired receptor-mediated activation of GPIIb-IIIa and pleckstrin phosphorylation: proteins regulated by CBFA2 play a role in GPIIb-IIIa activation.","date":"2003","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/14525764","citation_count":62,"is_preprint":false},{"pmid":"17644514","id":"PMC_17644514","title":"Beta2-integrins and acquired glycoprotein IIb/IIIa (GPIIb/IIIa) receptors cooperate in NF-kappaB activation of human neutrophils.","date":"2007","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/17644514","citation_count":61,"is_preprint":false},{"pmid":"16801104","id":"PMC_16801104","title":"Blockade of GpIIb/IIIa inhibits the release of vascular endothelial growth factor (VEGF) from tumor cell-activated platelets and experimental metastasis.","date":"1999","source":"Platelets","url":"https://pubmed.ncbi.nlm.nih.gov/16801104","citation_count":60,"is_preprint":false},{"pmid":"9637652","id":"PMC_9637652","title":"In vitro hypothermia enhances platelet GPIIb-IIIa activation and P-selectin expression.","date":"1998","source":"Anesthesiology","url":"https://pubmed.ncbi.nlm.nih.gov/9637652","citation_count":58,"is_preprint":false},{"pmid":"1832937","id":"PMC_1832937","title":"Anti-GPIIb/IIIa (CD41) monoclonal antibody-induced platelet activation requires Fc receptor-dependent cell-cell interaction.","date":"1991","source":"British journal of haematology","url":"https://pubmed.ncbi.nlm.nih.gov/1832937","citation_count":55,"is_preprint":false},{"pmid":"21415271","id":"PMC_21415271","title":"CD41 is developmentally regulated and differentially expressed on mouse hematopoietic stem cells.","date":"2011","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/21415271","citation_count":54,"is_preprint":false},{"pmid":"3345337","id":"PMC_3345337","title":"The localization of a platelet GpIIb-IIIa-related protein in endothelial cell adhesion structures.","date":"1988","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/3345337","citation_count":53,"is_preprint":false},{"pmid":"10510244","id":"PMC_10510244","title":"Platelet integrin GPIIb/IIIa: structure-function correlations. An update and lessons from other integrins.","date":"1999","source":"Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/10510244","citation_count":52,"is_preprint":false},{"pmid":"15134557","id":"PMC_15134557","title":"Oral GPIIb/IIIa antagonists: what went wrong?","date":"2004","source":"Current pharmaceutical design","url":"https://pubmed.ncbi.nlm.nih.gov/15134557","citation_count":52,"is_preprint":false},{"pmid":"21529934","id":"PMC_21529934","title":"Delineating the roles of the GPIIb/IIIa and GP-Ib-IX-V platelet receptors in mediating platelet adhesion to adsorbed fibrinogen and albumin.","date":"2011","source":"Biomaterials","url":"https://pubmed.ncbi.nlm.nih.gov/21529934","citation_count":49,"is_preprint":false},{"pmid":"20431845","id":"PMC_20431845","title":"Antagonism of P2Y12 or GPIIb/IIIa receptors reduces platelet-mediated myocardial injury after ischaemia and reperfusion in isolated rat hearts.","date":"2010","source":"Thrombosis and haemostasis","url":"https://pubmed.ncbi.nlm.nih.gov/20431845","citation_count":49,"is_preprint":false},{"pmid":"15670038","id":"PMC_15670038","title":"GPIIb-IIIa antagonists reduce thromboinflammatory processes in patients with acute coronary syndromes undergoing percutaneous coronary intervention.","date":"2005","source":"Journal of thrombosis and haemostasis : JTH","url":"https://pubmed.ncbi.nlm.nih.gov/15670038","citation_count":46,"is_preprint":false},{"pmid":"15121870","id":"PMC_15121870","title":"Extracellular signal-regulated kinase induces the megakaryocyte GPIIb/CD41 gene through MafB/Kreisler.","date":"2004","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/15121870","citation_count":45,"is_preprint":false},{"pmid":"12743278","id":"PMC_12743278","title":"Formation of disulfide-linked complexes between the three minor envelope glycoproteins (GP2b, GP3, and GP4) of equine arteritis virus.","date":"2003","source":"Journal of virology","url":"https://pubmed.ncbi.nlm.nih.gov/12743278","citation_count":45,"is_preprint":false},{"pmid":"3676108","id":"PMC_3676108","title":"Quinine- and quinidine platelet antibodies can react with GPIIb/IIIa.","date":"1987","source":"British journal of haematology","url":"https://pubmed.ncbi.nlm.nih.gov/3676108","citation_count":45,"is_preprint":false},{"pmid":"21247395","id":"PMC_21247395","title":"Targeting the platelet integrin GPIIb/IIIa.","date":"2010","source":"Current pharmaceutical design","url":"https://pubmed.ncbi.nlm.nih.gov/21247395","citation_count":43,"is_preprint":false},{"pmid":"19691478","id":"PMC_19691478","title":"Molecular defects in ITGA2B and ITGB3 genes in patients with Glanzmann thrombasthenia.","date":"2009","source":"Journal of thrombosis and haemostasis : JTH","url":"https://pubmed.ncbi.nlm.nih.gov/19691478","citation_count":43,"is_preprint":false},{"pmid":"16463284","id":"PMC_16463284","title":"Molecular diversity of Glanzmann thrombasthenia in southern India: new insights into mRNA splicing and structure-function correlations of alphaIIbbeta3 integrin (ITGA2B, ITGB3).","date":"2006","source":"Human mutation","url":"https://pubmed.ncbi.nlm.nih.gov/16463284","citation_count":43,"is_preprint":false},{"pmid":"16268472","id":"PMC_16268472","title":"ADAM 15 is an adhesion receptor for platelet GPIIb-IIIa and induces platelet activation.","date":"2005","source":"Thrombosis and haemostasis","url":"https://pubmed.ncbi.nlm.nih.gov/16268472","citation_count":43,"is_preprint":false},{"pmid":"12131559","id":"PMC_12131559","title":"Anti-platelet effects of GPIIb/IIIa and P-selectin antagonism, platelet activation, and binding to neutrophils.","date":"2002","source":"Journal of cardiovascular pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/12131559","citation_count":43,"is_preprint":false},{"pmid":"1540596","id":"PMC_1540596","title":"Role of the transmembrane and cytoplasmic domains in the assembly and surface exposure of the platelet integrin GPIIb/IIIa.","date":"1992","source":"Biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/1540596","citation_count":40,"is_preprint":false},{"pmid":"15546949","id":"PMC_15546949","title":"Differential requirements for calcium and Src family kinases in platelet GPIIb/IIIa activation and thromboxane generation downstream of different G-protein pathways.","date":"2004","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/15546949","citation_count":40,"is_preprint":false},{"pmid":"2345548","id":"PMC_2345548","title":"GPIIb and GPIIIa amino acid sequences deduced from human megakaryocyte cDNAs.","date":"1990","source":"Molecular biology reports","url":"https://pubmed.ncbi.nlm.nih.gov/2345548","citation_count":40,"is_preprint":false},{"pmid":"18252864","id":"PMC_18252864","title":"Modulation of murine embryonic stem cell-derived CD41+c-kit+ hematopoietic progenitors by ectopic expression of Cdx genes.","date":"2008","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/18252864","citation_count":38,"is_preprint":false},{"pmid":"25139854","id":"PMC_25139854","title":"Runx1 is required for progression of CD41+ embryonic precursors into HSCs but not prior to this.","date":"2014","source":"Development (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/25139854","citation_count":38,"is_preprint":false},{"pmid":"1459176","id":"PMC_1459176","title":"Increased GPIIB/IIIA expression and altered DNA-ploidy pattern in megakaryocytes of diabetic BB-rats.","date":"1992","source":"European journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/1459176","citation_count":37,"is_preprint":false},{"pmid":"32341357","id":"PMC_32341357","title":"CD41-deficient exosomes from non-traumatic femoral head necrosis tissues impair osteogenic differentiation and migration of mesenchymal stem cells.","date":"2020","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/32341357","citation_count":36,"is_preprint":false},{"pmid":"11033455","id":"PMC_11033455","title":"Potential future clinical applications for the GPIIb/IIIa antagonist, abciximab in thrombosis, vascular and oncological indications.","date":"2000","source":"Pathology oncology research : POR","url":"https://pubmed.ncbi.nlm.nih.gov/11033455","citation_count":36,"is_preprint":false},{"pmid":"14617694","id":"PMC_14617694","title":"Reversibility versus persistence of GPIIb/IIIa blocker-induced conformational change of GPIIb/IIIa (alphaIIbbeta3, CD41/CD61).","date":"2003","source":"The Journal of pharmacology and experimental therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/14617694","citation_count":35,"is_preprint":false},{"pmid":"25446279","id":"PMC_25446279","title":"CD41 marks the initial myelo-erythroid lineage specification in adult mouse hematopoiesis: redefinition of murine common myeloid progenitor.","date":"2015","source":"Stem cells (Dayton, Ohio)","url":"https://pubmed.ncbi.nlm.nih.gov/25446279","citation_count":35,"is_preprint":false},{"pmid":"19888429","id":"PMC_19888429","title":"The roles of platelet GPIIb/IIIa and alphavbeta3 integrins during HeLa cells adhesion, migration, and invasion to monolayer endothelium under static and dynamic shear flow.","date":"2009","source":"Journal of biomedicine & biotechnology","url":"https://pubmed.ncbi.nlm.nih.gov/19888429","citation_count":34,"is_preprint":false},{"pmid":"33496739","id":"PMC_33496739","title":"Specifications of the variant curation guidelines for ITGA2B/ITGB3: ClinGen Platelet Disorder Variant Curation Panel.","date":"2021","source":"Blood advances","url":"https://pubmed.ncbi.nlm.nih.gov/33496739","citation_count":32,"is_preprint":false},{"pmid":"14645556","id":"PMC_14645556","title":"Intra- and intermolecular disulfide bonds of the GP2b glycoprotein of equine arteritis virus: relevance for virus assembly and infectivity.","date":"2003","source":"Journal of virology","url":"https://pubmed.ncbi.nlm.nih.gov/14645556","citation_count":31,"is_preprint":false},{"pmid":"20020534","id":"PMC_20020534","title":"AlphaIIbbeta3 integrin: new allelic variants in Glanzmann thrombasthenia, effects on ITGA2B and ITGB3 mRNA splicing, expression, and structure-function.","date":"2010","source":"Human mutation","url":"https://pubmed.ncbi.nlm.nih.gov/20020534","citation_count":31,"is_preprint":false},{"pmid":"8979134","id":"PMC_8979134","title":"The anti-GPIIb-IIIa agents: fundamental and clinical aspects.","date":"1996","source":"Haemostasis","url":"https://pubmed.ncbi.nlm.nih.gov/8979134","citation_count":31,"is_preprint":false},{"pmid":"17501906","id":"PMC_17501906","title":"Distinct hemogenic potential of endothelial cells and CD41+ cells in mouse embryos.","date":"2007","source":"Development, growth & differentiation","url":"https://pubmed.ncbi.nlm.nih.gov/17501906","citation_count":30,"is_preprint":false},{"pmid":"1957276","id":"PMC_1957276","title":"Activation-independent exposure of the GPIIb-IIIa fibrinogen receptor.","date":"1991","source":"Thrombosis research","url":"https://pubmed.ncbi.nlm.nih.gov/1957276","citation_count":30,"is_preprint":false},{"pmid":"11154119","id":"PMC_11154119","title":"Differential expression of a ligand induced binding site (LIBS) by GPIIb-IIIa ligand recognition peptides and parenteral antagonists.","date":"2000","source":"Thrombosis and haemostasis","url":"https://pubmed.ncbi.nlm.nih.gov/11154119","citation_count":30,"is_preprint":false},{"pmid":"22952660","id":"PMC_22952660","title":"Itga2b regulation at the onset of definitive hematopoiesis and commitment to differentiation.","date":"2012","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/22952660","citation_count":29,"is_preprint":false},{"pmid":"11154120","id":"PMC_11154120","title":"Structure and function of murine alphaIIbbeta3 (GPIIb/IIIa): studies using monoclonal antibodies and beta3-null mice,","date":"2000","source":"Thrombosis and haemostasis","url":"https://pubmed.ncbi.nlm.nih.gov/11154120","citation_count":28,"is_preprint":false},{"pmid":"2207330","id":"PMC_2207330","title":"Monoclonal antibodies bound to subunits of the integrin GPIIb-IIIa are internalized and interfere with filopodia formation and platelet aggregation.","date":"1990","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/2207330","citation_count":28,"is_preprint":false},{"pmid":"8490951","id":"PMC_8490951","title":"Platelet GPIIb/IIIa receptor inhibition by SC-49992 prevents thrombosis and rethrombosis in the canine carotid artery.","date":"1993","source":"Cardiovascular research","url":"https://pubmed.ncbi.nlm.nih.gov/8490951","citation_count":27,"is_preprint":false},{"pmid":"10629587","id":"PMC_10629587","title":"Interleukin-6 and interleukin-11 act synergistically with thrombopoietin and stem cell factor to modulate ex vivo expansion of human CD41+ and CD61+ megakaryocytic cells.","date":"2000","source":"Haematologica","url":"https://pubmed.ncbi.nlm.nih.gov/10629587","citation_count":26,"is_preprint":false},{"pmid":"10195569","id":"PMC_10195569","title":"Cytokine-induced expansion of human CD34+ stem/progenitor and CD34+CD41+ early megakaryocytic marrow cells cultured on normal osteoblasts.","date":"1999","source":"Stem cells (Dayton, Ohio)","url":"https://pubmed.ncbi.nlm.nih.gov/10195569","citation_count":26,"is_preprint":false},{"pmid":"15781330","id":"PMC_15781330","title":"GPIIb (CD41) integrin is expressed on mast cells and influences their adhesion properties.","date":"2005","source":"Experimental hematology","url":"https://pubmed.ncbi.nlm.nih.gov/15781330","citation_count":25,"is_preprint":false},{"pmid":"37018659","id":"PMC_37018659","title":"Mechanosensing via a GpIIb/Src/14-3-3ζ axis critically regulates platelet migration in vascular inflammation.","date":"2023","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/37018659","citation_count":25,"is_preprint":false},{"pmid":"12601261","id":"PMC_12601261","title":"Comparison of the effects of cellulose triacetate and polysulfone membrane on GPIIb/IIIa and platelet activation.","date":"2003","source":"Blood purification","url":"https://pubmed.ncbi.nlm.nih.gov/12601261","citation_count":25,"is_preprint":false},{"pmid":"10557137","id":"PMC_10557137","title":"Antiplatelet therapies: from aspirin to GPIIb/IIIa-receptor antagonists and beyond.","date":"1999","source":"Drug discovery today","url":"https://pubmed.ncbi.nlm.nih.gov/10557137","citation_count":25,"is_preprint":false},{"pmid":"19487018","id":"PMC_19487018","title":"Regulation of CD40L (CD154) and CD62P (p-selectin) surface expression upon GPIIb-IIIa blockade of platelets from stable coronary artery disease patients.","date":"2009","source":"Thrombosis research","url":"https://pubmed.ncbi.nlm.nih.gov/19487018","citation_count":23,"is_preprint":false},{"pmid":"8904900","id":"PMC_8904900","title":"A nonsense mutation in the GPIIb heavy chain (Ser 870-->stop) impairs platelet GPIIb-IIIa expression.","date":"1996","source":"British journal of haematology","url":"https://pubmed.ncbi.nlm.nih.gov/8904900","citation_count":22,"is_preprint":false},{"pmid":"16634756","id":"PMC_16634756","title":"Cord blood in vitro expanded CD41 cells: identification of novel components of megakaryocytopoiesis.","date":"2006","source":"Journal of thrombosis and haemostasis : JTH","url":"https://pubmed.ncbi.nlm.nih.gov/16634756","citation_count":21,"is_preprint":false},{"pmid":"39195988","id":"PMC_39195988","title":"Foudroyant cerebral venous (sinus) thrombosis triggered through CLEC-2 and GPIIb/IIIa dependent platelet activation.","date":"2022","source":"Nature cardiovascular research","url":"https://pubmed.ncbi.nlm.nih.gov/39195988","citation_count":21,"is_preprint":false},{"pmid":"18220937","id":"PMC_18220937","title":"Platelet GPIIb/IIIa receptor antagonists in human ischemic brain disease.","date":"2008","source":"Current vascular pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/18220937","citation_count":20,"is_preprint":false},{"pmid":"18413191","id":"PMC_18413191","title":"Inhibition of platelet GPIIb-IIIa and P-selectin expression by aspirin is impaired by stress hyperglycemia.","date":"2008","source":"Journal of diabetes and its complications","url":"https://pubmed.ncbi.nlm.nih.gov/18413191","citation_count":20,"is_preprint":false},{"pmid":"7647005","id":"PMC_7647005","title":"Redistribution of GPIb/IX and GPIIb/IIIa during spreading of discoid platelets.","date":"1995","source":"British journal of haematology","url":"https://pubmed.ncbi.nlm.nih.gov/7647005","citation_count":20,"is_preprint":false},{"pmid":"24610714","id":"PMC_24610714","title":"CD41 is a reliable identification and activation marker for murine basophils in the steady state and during helminth and malarial infections.","date":"2014","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/24610714","citation_count":19,"is_preprint":false},{"pmid":"11746531","id":"PMC_11746531","title":"CD41+ and CD42+ hematopoietic progenitor cells may predict platelet engraftment after allogeneic peripheral blood stem cell transplantation.","date":"2001","source":"Journal of clinical apheresis","url":"https://pubmed.ncbi.nlm.nih.gov/11746531","citation_count":19,"is_preprint":false},{"pmid":"35676565","id":"PMC_35676565","title":"TLR4 inhibitor alleviates sepsis-induced organ failure by inhibiting platelet mtROS production, autophagy, and GPIIb/IIIa expression.","date":"2022","source":"Journal of bioenergetics and biomembranes","url":"https://pubmed.ncbi.nlm.nih.gov/35676565","citation_count":19,"is_preprint":false},{"pmid":"25771179","id":"PMC_25771179","title":"The Src tyrosine kinase Lck binds to CD2, CD4-1, and CD4-2 T cell co-receptors in channel catfish, Ictalurus punctatus.","date":"2015","source":"Molecular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/25771179","citation_count":18,"is_preprint":false},{"pmid":"9808053","id":"PMC_9808053","title":"In vitro expansion of CD34+/CD41+ cells from human peripheral blood CD34+/CD41- cells: role of cytokines for in vitro proliferation and differentiation of megakaryocytic progenitors.","date":"1998","source":"Experimental hematology","url":"https://pubmed.ncbi.nlm.nih.gov/9808053","citation_count":17,"is_preprint":false},{"pmid":"15497099","id":"PMC_15497099","title":"Thrombocytopenia resulting from sensitivity to GPIIb-IIIa inhibitors.","date":"2004","source":"Seminars in thrombosis and hemostasis","url":"https://pubmed.ncbi.nlm.nih.gov/15497099","citation_count":17,"is_preprint":false},{"pmid":"25298035","id":"PMC_25298035","title":"Thrombopoietin/MPL signaling confers growth and survival capacity to CD41-positive cells in a mouse model of Evi1 leukemia.","date":"2014","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/25298035","citation_count":17,"is_preprint":false},{"pmid":"17420226","id":"PMC_17420226","title":"CD41+/CD45+ cells without acetylcholinesterase activity are immature and a major megakaryocytic population in murine bone marrow.","date":"2007","source":"Stem cells (Dayton, Ohio)","url":"https://pubmed.ncbi.nlm.nih.gov/17420226","citation_count":16,"is_preprint":false},{"pmid":"31414106","id":"PMC_31414106","title":"Vincristine-loaded platelets coated with anti-CD41 mAbs: a new macrophage targeting proposal for the treatment of immune thrombocytopenia.","date":"2019","source":"Biomaterials science","url":"https://pubmed.ncbi.nlm.nih.gov/31414106","citation_count":16,"is_preprint":false},{"pmid":"12038797","id":"PMC_12038797","title":"Tirofiban blocks platelet adhesion to fibrin with minimal perturbation of GpIIb/IIIa structure.","date":"2002","source":"Thrombosis and haemostasis","url":"https://pubmed.ncbi.nlm.nih.gov/12038797","citation_count":16,"is_preprint":false},{"pmid":"39849453","id":"PMC_39849453","title":"Synergistic anti-oxidative/anti-inflammatory treatment for acute lung injury with selenium based chlorogenic acid nanoparticles through modulating Mapk8ip1/MAPK and Itga2b/PI3k-AKT axis.","date":"2025","source":"Journal of nanobiotechnology","url":"https://pubmed.ncbi.nlm.nih.gov/39849453","citation_count":15,"is_preprint":false},{"pmid":"24474638","id":"PMC_24474638","title":"Association of platelet ITGA2B and ITGB3 polymorphisms with ex vivo antiplatelet effect of ticagrelor in healthy Chinese male subjects.","date":"2014","source":"International journal of hematology","url":"https://pubmed.ncbi.nlm.nih.gov/24474638","citation_count":15,"is_preprint":false},{"pmid":"15526708","id":"PMC_15526708","title":"The anti-platelet approach targeting the fibrinogen ligand of the GPIIB/IIIa receptor.","date":"2004","source":"Journal of peptide science : an official publication of the European Peptide Society","url":"https://pubmed.ncbi.nlm.nih.gov/15526708","citation_count":15,"is_preprint":false},{"pmid":"2645166","id":"PMC_2645166","title":"Bone marrow and tissue expression of gpIIb/IIIa, LFA-1, Mac-1 and gp150,95 glycoproteins.","date":"1989","source":"European journal of haematology","url":"https://pubmed.ncbi.nlm.nih.gov/2645166","citation_count":15,"is_preprint":false},{"pmid":"26221761","id":"PMC_26221761","title":"Internalization of Tissue Factor-Rich Microvesicles by Platelets Occurs Independently of GPIIb-IIIa, and Involves CD36 Receptor, Serotonin Transporter and Cytoskeletal Assembly.","date":"2015","source":"Journal of cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/26221761","citation_count":15,"is_preprint":false},{"pmid":"10073984","id":"PMC_10073984","title":"Increased serotonin receptor density and platelet GPIIb/IIIa activation among smokers.","date":"1999","source":"Arteriosclerosis, thrombosis, and vascular biology","url":"https://pubmed.ncbi.nlm.nih.gov/10073984","citation_count":14,"is_preprint":false},{"pmid":"10663616","id":"PMC_10663616","title":"Ex vivo expansion of CD34+/CD41+ late progenitors from enriched peripheral blood CD34+ cells.","date":"2000","source":"Annals of hematology","url":"https://pubmed.ncbi.nlm.nih.gov/10663616","citation_count":14,"is_preprint":false},{"pmid":"9647415","id":"PMC_9647415","title":"Novel technetium-99m-labeled platelet GPIIb/IIIa receptor antagonists as potential imaging agents for venous and arterial thrombosis.","date":"1998","source":"Coronary artery disease","url":"https://pubmed.ncbi.nlm.nih.gov/9647415","citation_count":14,"is_preprint":false},{"pmid":"10554819","id":"PMC_10554819","title":"Expression of CD41 and c-mpl does not indicate commitment to the megakaryocyte lineage during haemopoietic development.","date":"1999","source":"British journal of haematology","url":"https://pubmed.ncbi.nlm.nih.gov/10554819","citation_count":13,"is_preprint":false},{"pmid":"30630213","id":"PMC_30630213","title":"Novel Murine Model of Immune Thrombocytopaenia through Immunized CD41 Knockout Mice.","date":"2019","source":"Thrombosis and haemostasis","url":"https://pubmed.ncbi.nlm.nih.gov/30630213","citation_count":13,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":55537,"output_tokens":7275,"usd":0.137868,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":16481,"output_tokens":6150,"usd":0.118078,"stage2_stop_reason":"end_turn"},"total_usd":0.255946,"stage1_batch_id":"msgbatch_01DUPACZi7AAWwuZiUjseQF4","stage2_batch_id":"msgbatch_018yt7chE3f48PEFtDwtj6AE","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1987,\n      \"finding\": \"GPIIb is synthesized in megakaryocytes as a precursor of Mr 130,000 containing both alpha and beta subunits; this precursor is processed with a half-life of 4–5 h, converting high-mannose oligosaccharides to complex-type carbohydrates to yield mature GPIIb alpha (116 kDa) and GPIIb beta (25 kDa) subunits. GPIIIa polypeptide backbone is 90 kDa with no detectable post-translational processing of the chain.\",\n      \"method\": \"Pulse-chase metabolic labeling with [35S]methionine, immunoprecipitation with subunit-specific antibodies, tunicamycin/monensin treatment, endoglycosidase H digestion of purified human megakaryocytes\",\n      \"journal\": \"The Journal of cell biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vitro biosynthesis assay with multiple orthogonal biochemical methods (pulse-chase, glycosidase treatment, inhibitor studies) in primary human megakaryocytes\",\n      \"pmids\": [\"3108266\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1989,\n      \"finding\": \"Assembly of pro-GPIIb with GPIIIa is an obligatory step for maturation of the GPIIb-IIIa heterodimer and its surface expression. A large pool (~60%) of unassociated GPIIIa exists and is not surface-exposed; GPIIb and pro-GPIIb molecules are nearly all found associated with GPIIIa. Expression of GPIIIa in a megakaryocytic cell line that only produces pro-GPIIb (and cannot process it) rescues mature GPIIb production and surface expression of the complex.\",\n      \"method\": \"Pulse-chase experiments, immunoprecipitation with subunit-specific antibodies on human megakaryocytes and the LAMA-84 megakaryocytic cell line, co-transfection rescue experiments\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — reconstitution/rescue experiment plus pulse-chase, reciprocal IP, replicated in two cell systems\",\n      \"pmids\": [\"2477081\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1990,\n      \"finding\": \"Full-length cDNA sequences for GPIIb and GPIIIa were determined from human megakaryocyte cDNA libraries, revealing a nucleotide difference at position 633 of GPIIb (cysteine in megakaryocyte vs. serine in HEL cells) and differences in GPIIIa sequence compared to endothelial cell-derived cDNA.\",\n      \"method\": \"cDNA library construction from human megakaryocytes, cDNA sequencing\",\n      \"journal\": \"Molecular biology reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Weak — primary sequence determination from megakaryocyte cDNA, single lab, single method\",\n      \"pmids\": [\"2345548\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1991,\n      \"finding\": \"The 5'-flanking region of the GPIIb gene (from -643 to +33) drives megakaryocyte-specific transcription. Two domains at positions -460 and -510 interact exclusively with proteins present in megakaryocytic cells and act as positive transcription factor binding sites; deletion of this region significantly decreases promoter activity. Other domains (at -54, -233, -345, -540) bind more broadly expressed nuclear factors.\",\n      \"method\": \"CAT reporter transfection in megakaryocytic and non-megakaryocytic cells, DNase I footprinting, gel mobility shift assays\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — functional promoter deletion analysis combined with protein-DNA interaction assays (footprinting + EMSA), single lab with multiple orthogonal methods\",\n      \"pmids\": [\"2026605\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1992,\n      \"finding\": \"The transmembrane and cytoplasmic domains of the GPIIb (alphaIIb) subunit are necessary for surface expression of the GPIIb-IIIa complex, whereas the corresponding domains of GPIIIa (beta3) are not required. The extracellular domains of both subunits can form a heterodimer in the absence of transmembrane/cytoplasmic domains, albeit with lower efficiency.\",\n      \"method\": \"COS cell transfection with full-length and deletion mutant cDNAs (GPIIb delta1 lacking TM/cytoplasmic domain; GPIIIa delta-m lacking TM/cytoplasmic domain), immunoprecipitation, immunofluorescence\",\n      \"journal\": \"Biochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — domain deletion mutagenesis with functional surface expression readout and Co-IP, single lab with multiple orthogonal methods\",\n      \"pmids\": [\"1540596\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1991,\n      \"finding\": \"Binding of the anti-GPIIIa monoclonal antibody D3GP3 to GPIIIa within intact GPIIb-IIIa complexes induces fibrinogen binding and platelet aggregation without triggering Ca2+ mobilization, protein phosphorylation, or pertussis toxin-sensitive G-protein activation, and the aggregation is not blocked by PGE1, aspirin, or apyrase. This demonstrates that a conformational change in GPIIb-IIIa can expose the fibrinogen receptor in an activation-independent fashion.\",\n      \"method\": \"Platelet aggregometry, Ca2+ mobilization assay, protein phosphorylation analysis, pertussis toxin treatment, pharmacologic inhibitor panel, scanning electron microscopy\",\n      \"journal\": \"Thrombosis research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — antibody-induced conformational change with multiple functional readouts and pharmacologic controls, single lab\",\n      \"pmids\": [\"1957276\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1991,\n      \"finding\": \"Anti-CD41 IgG antibody (UR1) activates platelets via an Fc receptor-dependent cell-cell interaction mechanism: UR1 binds CD41 on one platelet forming immune complexes that then crosslink and stimulate FcgammaRII on adjacent platelets. F(ab')2 fragments of UR1 fail to activate platelets and inhibit IgG-mediated activation; anti-FcgammaRII antibody blocks activation; high-viscosity media that impede cell-cell contact inhibit activation.\",\n      \"method\": \"Platelet aggregometry, Ca2+ mobilization assay, F(ab')2 fragment generation, anti-FcgammaRII blocking antibody, high-viscosity inhibition, cell-mixing experiments\",\n      \"journal\": \"British journal of haematology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal experiments (F(ab')2, receptor blocking, cell mixing, viscosity) converging on same mechanism\",\n      \"pmids\": [\"1832937\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"GPIIb-IIIa (alphaIIbbeta3) is the platelet receptor for fibrinogen and mediates platelet aggregation induced by all physiologic agonists; blockade with the Fab fragment of chimeric monoclonal antibody 7E3 (abciximab), RGD-containing snake venom peptides, or RGD-based peptidomimetics abolishes platelet aggregation and platelet thrombus formation.\",\n      \"method\": \"In vitro platelet aggregation assay, in vivo animal thrombosis models, EPIC Phase III clinical trial\",\n      \"journal\": \"Thrombosis and haemostasis\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — replicated across multiple labs, animal models, and a large clinical trial; multiple inhibitor classes converge on same receptor-ligand mechanism\",\n      \"pmids\": [\"8578476\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"A homozygous nonsense mutation (Ser870→stop) in the GPIIb heavy chain truncates GPIIb by 138 amino acids, removing the transmembrane and intracytoplasmic domains. The truncated GPIIb can associate with GPIIIa, but the heterodimer fails to mature (as shown by endoglycosidase H sensitivity) and is not expressed on the cell surface, establishing that the GPIIb light chain region is required for maturation and surface trafficking.\",\n      \"method\": \"Cotransfection of mutant GPIIb and wild-type GPIIIa in COS-7 cells, immunoprecipitation, endoglycosidase H digestion, flow cytometry\",\n      \"journal\": \"British journal of haematology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — disease mutation with reconstitution in COS cells, endoglycosidase H assay to assess maturation, and surface expression readout; single lab with multiple orthogonal methods\",\n      \"pmids\": [\"8904900\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"ERK signaling promotes megakaryocyte differentiation by driving transcription from the proximal GPIIb (CD41) promoter (within 114 bp upstream of the TSS). GATA, Ets, and Sp1 consensus sequences within this region each function combinatorially and are each necessary for ERK-activated transcription. ERK induces MafB/Kreisler, which synergizes with GATA and Ets factors to enhance GPIIb promoter activity; dominant-negative or antisense suppression of MafB inhibits ERK-dependent transactivation.\",\n      \"method\": \"Promoter-reporter transfection assays, site-directed mutagenesis of GATA/Ets/Sp1 sites, dominant-negative and antisense MafB constructs, megakaryocyte differentiation assays\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — multiple orthogonal promoter deletion/mutagenesis experiments with loss-of-function of MafB, single lab\",\n      \"pmids\": [\"15121870\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"Combined G(i) and G(z) signaling pathways activate platelet GPIIb/IIIa and cause platelet aggregation through a mechanism that requires Src family tyrosine kinases but shows only a minor calcium requirement, distinct from the G(q)+G(i) pathway which is dependent on intracellular calcium but insensitive to Src family kinase inhibitors. Src family kinase inhibitor PP2 inhibits PAC-1 binding (GPIIb/IIIa activation) and thromboxane generation downstream of G(i)+G(z) but not G(q)+G(i).\",\n      \"method\": \"Platelet aggregometry, PAC-1 binding by flow cytometry, intracellular calcium chelation (BAPTA-AM), PP2 Src kinase inhibition, aspirin treatment, G-protein pathway-selective agonists, P2Y1-deficient and Galpha(q)-deficient mouse platelets\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic knockout mice plus pharmacologic dissection using multiple selective inhibitors and multiple readouts, single lab with strong convergent evidence\",\n      \"pmids\": [\"15546949\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"CBFA2 (RUNX1) mutation in a patient is associated with decreased platelet PKC-theta and impaired receptor-mediated GPIIb-IIIa activation and pleckstrin phosphorylation, demonstrating that PKC-theta and proteins regulated by CBFA2 are required for inside-out signal transduction leading to GPIIb-IIIa activation.\",\n      \"method\": \"Platelet RNA sequencing (exon amplification), immunoblotting for PKC isoforms and pleckstrin, flow cytometry for GPIIb-IIIa activation (PAC-1), functional aggregation assays\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — single patient with multiple biochemical readouts linking transcription factor mutation to integrin activation pathway; single lab, limited to one case\",\n      \"pmids\": [\"14525764\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"ADAM15 (metargidin) functions as an adhesion receptor for platelet GPIIb-IIIa. Soluble ADAM15 binds to activated but not resting GPIIb-IIIa. Platelet adhesion to immobilized ADAM15 is blocked by anti-alphaIIbbeta3 mAbs (7E3, 2G12) but not by anti-alphavbeta3 (LM609). Adhesion to ADAM15 triggers platelet activation including CD62P secretion and CD40L release.\",\n      \"method\": \"Platelet adhesion assay under static and shear conditions, neutralizing anti-integrin mAbs, flow cytometry for activation markers (CD62P, CD40L), ADAM15 overexpression on endothelial cells\",\n      \"journal\": \"Thrombosis and haemostasis\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — binding specificity established with multiple blocking antibodies and multiple activation readouts; single lab\",\n      \"pmids\": [\"16268472\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"S. aureus fibronectin-binding proteins FnBPA and FnBPB activate platelets via two distinct bridges to the low-affinity form of GPIIb/IIIa on resting platelets: (i) fibrinogen bridging to the A domain and (ii) fibronectin bridging to the BCD region. Antibodies recognizing FnBPA engage platelet FcgammaRIIa to complete activation; blocking GPIIb/IIIa or FcgammaRIIa (mAb IV-3) inhibits activation.\",\n      \"method\": \"Platelet aggregation assays, domain-truncation constructs of FnBPA expressed on S. aureus and L. lactis, blocking antibodies against GPIIb/IIIa and FcgammaRIIa\",\n      \"journal\": \"Molecular microbiology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple truncation constructs dissecting two independent mechanisms, receptor-blocking experiments, heterologous expression system; replicated across multiple bacterial strains\",\n      \"pmids\": [\"16359330\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"Platelet-derived microparticles (PMPs) transfer functional GPIIb/IIIa receptors to neutrophils. On GM-CSF-treated neutrophils, acquired GPIIb/IIIa co-localizes with beta2-integrins and cooperates with them to activate NF-kappaB via Src, Syk, and the actin cytoskeleton. Blocking either beta2-integrins or GPIIb/IIIa abrogates fibronectin-induced NF-kappaB activation and TNF-alpha mRNA upregulation in PMP-loaded neutrophils.\",\n      \"method\": \"Flow cytometry and confocal microscopy for receptor surface expression, NF-kappaB Western blot and EMSA, RT-PCR for TNF-alpha, kinase inhibitors (Src, Syk), blocking antibodies, therapeutic GPIIb/IIIa inhibitors\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — confocal co-localization plus functional NF-kappaB assays with multiple inhibitors; single lab\",\n      \"pmids\": [\"17644514\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"A heterozygous ITGA2B R995W (αIIb-W995) mutation induces constitutive activation of the αIIbβ3 receptor as shown by spontaneous PAC-1 and fibrinogen binding to resting platelets, and spontaneous FAK phosphorylation in transfected 293T cells. The activated αIIb-W995/β3 causes membrane ruffling and abnormal cytoplasmic protrusions in transfected CHO cells, and increases proplatelet tip size/decreases tip number in mouse fetal liver-derived megakaryocytes, establishing a mechanism for congenital macrothrombocytopenia.\",\n      \"method\": \"Flow cytometry (PAC-1, fibrinogen binding), FAK phosphorylation by Western blot, 293T and CHO cell transfection with mutant constructs, mouse fetal liver megakaryocyte transduction, proplatelet formation assay\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — multiple orthogonal functional assays (binding, phosphorylation, morphology, proplatelet formation), cell-based reconstitution in multiple systems, confirmed in 4 unrelated families\",\n      \"pmids\": [\"21454453\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"Itga2b expression in hematopoietic cells is regulated by lineage-specific epigenetic mechanisms: H4K8 acetylation marks the locus in megakaryocytes, while H3K27me3 represses it in multipotential hematopoietic progenitors (HPC7 cells). Commitment to megakaryocyte differentiation is accompanied by upregulation of the H3K27 demethylase Jmjd3, which correlates with decreased H3K27me3 at the Itga2b locus and increased CD41 expression. An internal promoter mechanism also participates in developmental regulation.\",\n      \"method\": \"Chromatin immunoprecipitation (H4K8ac, H3K27me3), RT-PCR for Jmjd3 and Itga2b, promoter analysis in multiple hematopoietic cell contexts\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP for histone marks and correlation with Jmjd3 induction, multiple cell types; single lab, correlative element without Jmjd3 direct KO at this locus\",\n      \"pmids\": [\"22952660\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"Integrin GPIIb (αIIb)-dependent outside-in signaling via Gα13 coordinates platelet polarization during migration by triggering a c-Src/14-3-3ζ-dependent lamellipodium formation pathway. This pathway is independent of soluble agonists or chemotactic signals and requires anisotropic myosin IIa activity at the platelet rear preceded by polarized actin polymerization at the front. Dasatinib (ABL/c-Src inhibitor) and other inhibitors of this cascade selectively impair platelet migration without major effects on classical platelet functions.\",\n      \"method\": \"Time-resolved morphodynamic profiling of individual platelets, pharmacologic inhibitors (dasatinib and others), murine inflammation models with 4D intravital microscopy, patient platelets from dasatinib-treated leukemia patients, actin/myosin perturbation experiments\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal methods (live imaging, pharmacology, in vivo mouse models, patient samples), pathway dissection with selective inhibitors, replicated across systems\",\n      \"pmids\": [\"37018659\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"CD41 (integrin α2b) in exosomes activates a CD41-integrin β3-FAK-Akt-Runx2 signaling pathway to support osteogenic differentiation and migration of mesenchymal stem cells. Exosomes from osteonecrosis of the femoral head (ONFH) tissue are deficient in CD41, and downregulation of CD41 in normal exosomes impairs this pathway and reduces MSC osteogenic differentiation and migration.\",\n      \"method\": \"Proteomic analysis of ONFH exosomes vs. normal exosomes, siRNA knockdown of CD41 in MSCs, Western blot for FAK/Akt/Runx2 phosphorylation, osteogenic differentiation assays, migration assays, rat in vivo ONFH model\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — loss-of-function (siRNA) with defined pathway readout (FAK-Akt-Runx2 phosphorylation) and functional cellular phenotype; single lab\",\n      \"pmids\": [\"32341357\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1988,\n      \"finding\": \"A GPIIb-IIIa-related protein in endothelial cells localizes to vinculin-rich focal contacts at stress fiber membrane insertions and to cell-to-cell contacts. Anti-GPIIb-IIIa antibodies added to endothelial cell suspensions inhibit spreading on fibrinogen and vitronectin substrata but are poorly active on fibronectin; antibodies added to adherent cells disrupt cell-to-cell contacts and cause rounding and detachment.\",\n      \"method\": \"Immunofluorescence localization, polyclonal anti-GPIIb-IIIa antibody inhibition of endothelial cell spreading on different matrix substrates, antibody-induced detachment assay\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct localization by immunofluorescence with functional consequence (inhibition of spreading and adhesion); note this uses a cross-reactive endothelial form; single lab\",\n      \"pmids\": [\"3345337\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1990,\n      \"finding\": \"When platelets are treated with monoclonal antibodies Tab (anti-GPIIb) and AP3 (anti-GPIIIa) together and stimulated with ADP, they form short blunted projections instead of normal filopodia, sequester GPIIb-IIIa and fibrinogen into the surface-connected canalicular system via massive actomyosin-controlled membrane flow, and fail to aggregate despite normal fibrinogen binding. This indicates that GPIIb-IIIa plays a role in signaling cytoskeletal rearrangements required for filopodium formation and aggregation.\",\n      \"method\": \"Scanning and transmission electron microscopy, immunolabel-surface replication, immunocytochemistry on frozen sections, biochemical cytoskeletal activation assays, platelet aggregometry\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple ultrastructural and biochemical methods characterizing a distinct post-fibrinogen-binding defect; single lab\",\n      \"pmids\": [\"2207330\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"During platelet spreading, GPIIb-IIIa complexes pre-labeled with fibrinogen-coated gold particles translocate from uniform surface distribution to caps over cell centers and into channels of the open canalicular system (OCS), while GPIb/IX pre-labeled with vWF moves with the expanding cell membrane toward peripheral margins. These two receptor populations thus undergo distinct directional redistribution during spreading.\",\n      \"method\": \"Pre-labeling of discoid platelets with fibrinogen-coated gold or vWF/protein A-gold, electron microscopy, immunolabel-surface replication, cytochalasin E treatment to preserve discoid shape\",\n      \"journal\": \"British journal of haematology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct ultrastructural localization with specific gold-labeled ligands tracking receptor movement during defined functional event; single lab\",\n      \"pmids\": [\"7647005\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Cooperative signaling of platelet CLEC-2 and GPIIb/IIIa triggers cerebral venous sinus thrombosis (CVT)-like syndrome in mice within minutes. Pharmacological inhibition of GPIIb/IIIa (or CLEC-2 signaling) completely blocks platelet activation and CVT, and GPIIb/IIIa blockade after onset of neurological symptoms rescues mice from platelet consumption and death, demonstrating a mechanistic role for GPIIb/IIIa in pathological platelet activation underlying CVT.\",\n      \"method\": \"Antibody-induced mouse CVT model (INU1-fab), intravital transcranial microscopy, pharmacologic GPIIb/IIIa inhibition, CLEC-2 signaling blockade, heparin comparison, brain autopsy\",\n      \"journal\": \"Nature cardiovascular research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — in vivo mouse model with real-time intravital imaging, genetic/pharmacologic dissection of two receptor pathways, therapeutic rescue experiment\",\n      \"pmids\": [\"39195988\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"GPIIb (CD41) integrin is expressed on cultured bone marrow mast cells (human and murine). Loss of GPIIb in gpIIb-/- mice does not affect mast cell growth or differentiation markers but results in altered adhesion to fibronectin- and vitronectin-coated surfaces and increased surface expression of αV integrin as a compensatory response.\",\n      \"method\": \"Flow cytometry of bone marrow mast cells from wild-type and gpIIb-/- mice, adhesion assays on matrix-coated surfaces, analysis of peritoneal mast cells in vivo\",\n      \"journal\": \"Experimental hematology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — knockout mouse comparison with functional adhesion assay and in vivo tissue mast cell analysis; single lab\",\n      \"pmids\": [\"15781330\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"ITGA2B (αIIb) assembles co-translationally with GPIIIa (β3) as an obligate prerequisite for heterodimer maturation and surface expression; the transmembrane/cytoplasmic domain of αIIb is required for surface trafficking while that of β3 is dispensable; on the platelet surface the αIIbβ3 complex is maintained in a low-affinity state and is activated by inside-out signaling through convergent G-protein pathways (Gq+Gi or Gi+Gz, the latter requiring Src family kinases) to bind fibrinogen, von Willebrand factor, and other RGD-containing ligands and mediate platelet aggregation; outside-in signaling through αIIb via Gα13 and a c-Src/14-3-3ζ axis drives lamellipodia formation and platelet migration; gain-of-function mutations (e.g. R995W) constitutively activate the receptor, causing macrothrombocytopenia through defective proplatelet formation; tissue-specific transcription is controlled by megakaryocyte-specific promoter elements binding GATA, Ets, Sp1, and ERK-induced MafB/Kreisler factors, and the locus is epigenetically regulated by H3K27me3/Jmjd3 during hematopoietic commitment.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"ITGA2B (\\u03b1IIb/GPIIb) is the platelet-specific \\u03b1 subunit that pairs obligately with \\u03b23 (GPIIIa) to form the \\u03b1IIb\\u03b23 (GPIIb-IIIa) integrin, the principal receptor mediating fibrinogen binding and platelet aggregation induced by physiologic agonists [#7]. The subunit is synthesized in megakaryocytes as a glycosylated precursor whose assembly with \\u03b23 is an obligatory checkpoint for heterodimer maturation and surface expression; unassembled \\u03b23 is retained intracellularly, and co-expression of \\u03b23 rescues maturation of \\u03b1IIb [#0, #1]. The transmembrane and cytoplasmic domains of \\u03b1IIb \\u2014 but not those of \\u03b23 \\u2014 are required for surface trafficking of the complex, a requirement underscored by a disease truncation (Ser870\\u2192stop) that permits heterodimer association yet abolishes maturation and surface display [#4, #8]. On the platelet surface the receptor is held in a low-affinity state and switches to a fibrinogen-competent conformation through inside-out signaling; convergent G-protein routes (Gq+Gi versus Gi+Gz) drive this activation, with the Gi+Gz pathway requiring Src-family kinases and the Gq+Gi pathway being calcium-dependent [#10], and upstream transcription-factor programs (RUNX1/CBFA2-PKC\\u03b8) feed into this inside-out cascade [#11]. Beyond ligand capture, \\u03b1IIb-dependent outside-in signaling through G\\u03b113 and a c-Src/14-3-3\\u03b6 axis organizes lamellipodium formation and directional platelet migration [#17], and the engaged receptor couples to actomyosin-driven cytoskeletal rearrangement required for filopodium formation and aggregation [#20]. A gain-of-function mutation (R995W) constitutively activates the receptor, producing spontaneous ligand binding and FAK phosphorylation and causing macrothrombocytopenia through defective proplatelet formation [#15]. Transcription of the gene is restricted to the megakaryocytic lineage by promoter elements bound combinatorially by GATA, Ets, and Sp1 factors and by ERK-induced MafB, and the locus is epigenetically gated by H3K27me3/Jmjd3 during hematopoietic commitment [#3, #9, #16]. The receptor also participates in pathological thrombosis (e.g., CLEC-2\\u2013cooperative cerebral venous sinus thrombosis) and serves as a validated antithrombotic drug target [#7, #22].\",\n  \"teleology\": [\n    {\n      \"year\": 1987,\n      \"claim\": \"Established how \\u03b1IIb is produced and processed in its native cell, defining the biosynthetic substrate from which the mature receptor is built.\",\n      \"evidence\": \"Pulse-chase metabolic labeling with glycosidase/inhibitor treatment in primary human megakaryocytes\",\n      \"pmids\": [\"3108266\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not address how assembly with \\u03b23 controls processing\", \"No structural detail of the precursor\"]\n    },\n    {\n      \"year\": 1989,\n      \"claim\": \"Showed that \\u03b1IIb-\\u03b23 assembly is the obligatory gate for heterodimer maturation and surface expression, explaining why neither subunit reaches the surface alone.\",\n      \"evidence\": \"Pulse-chase, reciprocal immunoprecipitation, and \\u03b23 co-expression rescue in megakaryocytes and the LAMA-84 cell line\",\n      \"pmids\": [\"2477081\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not map which domains mediate the assembly requirement\", \"ER retention machinery for unassembled subunits not identified\"]\n    },\n    {\n      \"year\": 1990,\n      \"claim\": \"Determined the full-length \\u03b1IIb (and \\u03b23) coding sequence, providing the molecular framework for mutagenesis and disease-variant analysis.\",\n      \"evidence\": \"cDNA library construction and sequencing from human megakaryocytes\",\n      \"pmids\": [\"2345548\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single-lab sequence; cell-type sequence differences not functionally validated\", \"No structure-function annotation\"]\n    },\n    {\n      \"year\": 1991,\n      \"claim\": \"Localized the megakaryocyte-specific transcriptional control to defined 5'-flanking elements, beginning the explanation of why the gene is lineage-restricted.\",\n      \"evidence\": \"CAT reporter deletions, DNase I footprinting, and EMSA in megakaryocytic vs non-megakaryocytic cells\",\n      \"pmids\": [\"2026605\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Identity of the megakaryocyte-specific binding factors not determined here\", \"Did not link promoter activity to differentiation signals\"]\n    },\n    {\n      \"year\": 1991,\n      \"claim\": \"Demonstrated that a conformational change in the heterodimer alone can expose the fibrinogen receptor, dissociating receptor activation from canonical intracellular signaling.\",\n      \"evidence\": \"Antibody (D3GP3)-induced aggregation with Ca2+, phosphorylation, G-protein, and pharmacologic controls\",\n      \"pmids\": [\"1957276\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Structural basis of the conformational switch not resolved\", \"Single-lab antibody-based perturbation\"]\n    },\n    {\n      \"year\": 1991,\n      \"claim\": \"Clarified that some anti-CD41 antibodies activate platelets indirectly via FcgammaRII crosslinking rather than through direct receptor signaling, distinguishing artefactual from intrinsic activation.\",\n      \"evidence\": \"F(ab')2 fragments, anti-FcgammaRII blockade, cell-mixing and viscosity experiments\",\n      \"pmids\": [\"1832937\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Does not address physiologic inside-out activation\", \"Mechanism specific to IgG immune complexes\"]\n    },\n    {\n      \"year\": 1992,\n      \"claim\": \"Mapped the trafficking determinant to the \\u03b1IIb transmembrane/cytoplasmic region, showing \\u03b23's cytoplasmic tail is dispensable for surface expression.\",\n      \"evidence\": \"COS-cell transfection with TM/cytoplasmic deletion mutants, Co-IP, and immunofluorescence\",\n      \"pmids\": [\"1540596\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not identify the trafficking machinery engaging the \\u03b1IIb tail\", \"Lower-efficiency extracellular dimerization not mechanistically explained\"]\n    },\n    {\n      \"year\": 1995,\n      \"claim\": \"Cemented \\u03b1IIb\\u03b23 as the universal fibrinogen receptor for platelet aggregation and validated it as an antithrombotic target across inhibitor classes.\",\n      \"evidence\": \"In vitro aggregation, animal thrombosis models, and a Phase III clinical trial with abciximab and RGD-based inhibitors\",\n      \"pmids\": [\"8578476\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not dissect upstream activation pathways\", \"Outside-in signaling roles not addressed\"]\n    },\n    {\n      \"year\": 1990,\n      \"claim\": \"Linked receptor engagement to actomyosin-driven cytoskeletal remodeling, revealing a signaling role beyond passive ligand binding.\",\n      \"evidence\": \"EM, immunolabel-surface replication, and cytoskeletal/aggregation assays with anti-GPIIb/anti-GPIIIa antibodies\",\n      \"pmids\": [\"2207330\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Molecular link between receptor and cytoskeleton not defined\", \"Antibody-clamping artifact not fully excluded\"]\n    },\n    {\n      \"year\": 1995,\n      \"claim\": \"Showed receptor-specific spatial sorting during spreading, with \\u03b1IIb\\u03b23 internalizing into the open canalicular system distinct from GPIb/IX redistribution.\",\n      \"evidence\": \"Gold-labeled ligand tracking by electron microscopy during platelet spreading\",\n      \"pmids\": [\"7647005\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Functional consequence of OCS sequestration unresolved\", \"Trafficking mechanism not identified\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Connected the RUNX1/CBFA2 transcriptional program to inside-out activation competence via PKC-theta and pleckstrin phosphorylation.\",\n      \"evidence\": \"Patient platelet analysis with immunoblotting, PAC-1 flow cytometry, and aggregation assays\",\n      \"pmids\": [\"14525764\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single-patient observation\", \"Direct RUNX1 targets controlling activation not fully enumerated\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Resolved two divergent G-protein routes to inside-out activation, distinguishing a calcium-dependent Gq+Gi pathway from a Src-kinase-dependent Gi+Gz pathway.\",\n      \"evidence\": \"Aggregometry, PAC-1 binding, calcium chelation, PP2 inhibition, and knockout-mouse platelets\",\n      \"pmids\": [\"15546949\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Convergence point on the integrin tail not identified\", \"Relative physiologic weighting of pathways unresolved\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Defined the proximal promoter logic, showing GATA/Ets/Sp1 and ERK-induced MafB act combinatorially to drive megakaryocytic CD41 transcription.\",\n      \"evidence\": \"Promoter-reporter mutagenesis and dominant-negative/antisense MafB in differentiation assays\",\n      \"pmids\": [\"15121870\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Endogenous chromatin context not addressed here\", \"Upstream ERK activators not specified\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Extended the receptor's repertoire to non-canonical ligands and cell contexts, identifying ADAM15 as an activation-dependent adhesion ligand and documenting CD41 roles in mast cells.\",\n      \"evidence\": \"Adhesion assays with blocking antibodies and activation-marker flow cytometry; gpIIb-/- mast cell adhesion studies\",\n      \"pmids\": [\"16268472\", \"15781330\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Physiologic relevance of ADAM15 engagement in vivo unclear\", \"Mast cell adhesion phenotype is compensatory and indirect\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Showed bacterial pathogens exploit the low-affinity receptor through fibrinogen/fibronectin bridges plus FcgammaRIIa, mechanistically linking \\u03b1IIb\\u03b23 to infective platelet activation.\",\n      \"evidence\": \"Aggregation assays with FnBPA truncation constructs in heterologous bacteria and receptor-blocking antibodies\",\n      \"pmids\": [\"16359330\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo contribution to endocarditis not tested here\", \"Does not address direct receptor conformation change\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Demonstrated horizontal transfer of functional \\u03b1IIb\\u03b23 to neutrophils, where it cooperates with \\u03b22-integrins to drive NF-kappaB signaling, broadening the receptor's inflammatory role.\",\n      \"evidence\": \"Confocal co-localization, NF-kappaB Western/EMSA, RT-PCR, and Src/Syk inhibitors in PMP-loaded neutrophils\",\n      \"pmids\": [\"17644514\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single-lab observation\", \"In vivo significance of transferred receptor unestablished\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Identified R995W as a constitutively activating mutation causing macrothrombocytopenia via defective proplatelet formation, mechanistically tying receptor activation state to thrombopoiesis.\",\n      \"evidence\": \"PAC-1/fibrinogen binding, FAK phosphorylation, cell-morphology assays, and proplatelet assays in transfected cells and fetal-liver megakaryocytes, confirmed in 4 families\",\n      \"pmids\": [\"21454453\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Precise structural mechanism of constitutive activation not detailed\", \"Link between activation and proplatelet defect mechanistically incomplete\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Added an epigenetic layer to lineage restriction, showing H3K27me3/Jmjd3 dynamics gate Itga2b expression during megakaryocytic commitment.\",\n      \"evidence\": \"ChIP for histone marks and RT-PCR for Jmjd3/Itga2b across hematopoietic cell types\",\n      \"pmids\": [\"22952660\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Correlative without direct Jmjd3 knockout at the locus\", \"Internal promoter mechanism not fully resolved\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Implicated CD41 in exosome-borne CD41\\u2013\\u03b23\\u2013FAK\\u2013Akt\\u2013Runx2 signaling supporting MSC osteogenesis, indicating a role outside hemostasis.\",\n      \"evidence\": \"Exosome proteomics, CD41 siRNA, FAK/Akt/Runx2 immunoblotting, and differentiation/migration assays with a rat ONFH model\",\n      \"pmids\": [\"32341357\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single-lab study\", \"How exosomal CD41 engages target-cell \\u03b23 not defined\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Established \\u03b1IIb\\u03b23 as a driver and therapeutic target in pathological thrombosis, with receptor blockade rescuing CLEC-2-cooperative cerebral venous sinus thrombosis.\",\n      \"evidence\": \"Antibody-induced mouse CVT model with intravital imaging, pharmacologic GPIIb/IIIa and CLEC-2 blockade, and therapeutic rescue\",\n      \"pmids\": [\"39195988\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular cooperation between CLEC-2 and \\u03b1IIb\\u03b23 signaling not fully mapped\", \"Translation to human CVT therapy untested here\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Defined an outside-in migration program in which \\u03b1IIb\\u03b23 couples to G\\u03b113 and a c-Src/14-3-3\\u03b6 axis to polarize platelets, distinguishing migration from classical aggregation.\",\n      \"evidence\": \"Morphodynamic profiling, selective inhibitors (dasatinib), 4D intravital microscopy, patient platelets, and actin/myosin perturbation\",\n      \"pmids\": [\"37018659\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of G\\u03b113 coupling to \\u03b1IIb tail unresolved\", \"Physiologic triggers of the polarization program not fully defined\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How inside-out and outside-in signals are integrated at the \\u03b1IIb cytoplasmic tail at the structural level, and how the same receptor switches between aggregation, migration, and pathological consumption programs, remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No structural model of the activated cytoplasmic tail signaling complex in the corpus\", \"Mechanistic determinants choosing migration vs aggregation outputs unknown\", \"Integration of transcriptional/epigenetic control with receptor signaling not unified\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0098631\", \"supporting_discovery_ids\": [7, 12, 19]},\n      {\"term_id\": \"GO:0060089\", \"supporting_discovery_ids\": [10, 17, 20]},\n      {\"term_id\": \"GO:0038024\", \"supporting_discovery_ids\": [7]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [1, 4, 21]},\n      {\"term_id\": \"GO:0005856\", \"supporting_discovery_ids\": [20, 17]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-109582\", \"supporting_discovery_ids\": [7, 10, 22]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [10, 17, 15]},\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [3, 9, 16]}\n    ],\n    \"complexes\": [\"\\u03b1IIb\\u03b23 (GPIIb-IIIa) integrin\"],\n    \"partners\": [\"ITGB3\", \"FGA\", \"ADAM15\", \"SRC\", \"YWHAZ\"],\n    \"other_free_text\": []\n  }\n}\n```","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":8,"faith_total":8,"faith_pct":100.0}}